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The human endocannabinoid system (ECS) modulates many vital physiological and 
neuromodulatory functions. It comprises lipid endocannabinoids, e.g. Anandamide (AEA), 
which are synthesized on demand and which bind to receptors (e.g. CB1, CB2) to elicit a 
response. Single-celled protists can respond to endocannabinoids despite not possessing any 
of the known cannabinoid receptors suggesting they possess a rudimentary ECS with an 
unknown target for the endocannabinoids.  
The ciliate Tetrahymena thermophila possesses a suite of endocannabinoids (including 
AEA), with N-palmitoylethanolamide (PEA) and N-oleoylethanolamide (OEA) being two of 
the dominant compounds. In humans, the natural receptor for the latter is the peroxisome 
proliferator-activated receptor alpha (PPARα) but this receptor has not been identified in the 
T. thermophila genome. It may be that Tetrahymena spp. possess a ‘PPAR-like’ receptor or 
they possess a different target, which mediate a reaction to these endocannabinoids. 
This study examined the potential role of ‘PPARs’ in the ECS of Tetrahymena pyriformis. 
Cell death was examined in the presence of agonists to each of the three known PPAR types, 
i.e. OEA/PEA/AEA/Cannabidiol (CBD) (to PPARα), GW0742 (to PPARβ/δ), and 
Rosiglitazone (PPARγ). All agonists induced ciliate cell death and all, except PEA and 
Rosiglitazone, gave IC50 values similar to those recorded for human cells (GW0742, 12 µM; 
OEA, 45 µM; AEA and CBD, 4 µM). The negative action of some of these agonists could be 
alleviated by blocking PPAR isoforms with their respective antagonists (GW6471 for 
PPARα, GSK3787 for PPARβ/δ, and T0070907 for PPARγ). The action of AEA and 
GW0742 were alleviated with all antagonists, CBD was only alleviated with GW6471 (for 
PPARα), and OEA was alleviated by none. Results suggest that T. pyriformis possesses a 
PPAR-like protein/target for AEA, CBD, and GW0742, but not for OEA. 
Since the target of OEA was not a PPAR, this study explored other potential targets by using 
antagonists against the Dopamine receptor (Haloperidol), Gαi/o (Pertussis toxin [PTX]), and 
Protein kinase A (H89).  Only PTX slightly alleviated the effect of OEA, suggesting a Gαi/o 
receptor mechanism.  
Although the results are preliminary, further study may lead to the mapping and deeper 
understanding of the nature of the ECS in Tetrahymena and these non-CB pathways may be a 
possible therapeutic target in key diseases such as cancer, obesity and diabetes.  
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1. Introduction 
The human endocannabinoid system (ECS) is essential in the modulation of many 
fundamental regulations from cellular activities to physiological functions such as 
neurodegeneration, psychosis and anxiety, cardiovascular, pain, and appetite (Bih et al., 
2015; Zou and Kumar, 2018). The ECS is a complex signaling pathway found throughout the 
body, being dominant in the brain, cardiovascular, nervous, reproductive, intestinal and the 
immune tissues (Zou and Kumar, 2018). This makes cannabinoids a novel therapeutic target 
for a range of diseases including cancer, diabetes, anxiety, addiction, epilepsy and many other 
neurological disorders including Parkinson’s and Alzheimer’s disease (Bih et al., 2015; Dariš 
et al., 2019).  
Many years of research has been dedicated to identifying and understanding the nature and 
individual components of the ECS, especially the effects of cannabinoid compounds such as 
cannabidiol (CBD), delta-9-tetrahydrocannabinol (Δ9-THC), 2-arahidonoyl glycerol (2-AG) 
and anadamide (AEA) upon it. However, studies have often been contradictory, suggesting a 
broad mechanism of action due to numerous possible receptors. As such, studying the 
endocannabinoid system in a simpler organism, which has no known receptors but can still 
respond to cannabinoids, may help to gain a better understanding of the nature of the ECS. 
The ciliate Tetrahymena is a single-celled eukaryote which is widely used as a model 
organism in biomedical studies due to its low maintenance, rapid growth and the availability 
of DNA and genomic data (Ruehle et al., 2016). The study of ECS in Tetrahymena may 
reveal interesting, yet, simpler signaling pathways of the eukaryotic ECS in general.  
This literature review explains the fundamental function of the ECS in humans and its main 
components; cannabinoid ligands, the four main receptors (both CB and non-CB), and their 
metabolizing enzymes. The review then provides evidence for a rudimentary ECS in single-
celled eukaryotes and in particular, in the ciliate Tetrahymena, which despite possessing none 
of the four main cannabinoid receptors, responds negatively to cannabinoids. This review 
then further explores the most likely potential cannabinoid receptors in this ciliate; the 
peroxisome proliferator-activated receptor (PPAR), Dopamine (D) and orphan G protein-
coupled receptors (GPCRs). 
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1.1. The human endocannabinoid system 
The human endocannabinoid system comprises cannabinoid receptors, together with their 
lipids ligand and the enzymes which synthesized and degrades them (Pertwee et al., 2010; Lu 
and Mackie, 2016). The system has a broad neuro-modulatory effect as well as non-neuronal 
effects such as the regulation of appetite through the gastrointestinal (GI) tract and fertility 
through the reproductive system (Izzo and Sharkey, 2010; Zou and Kumar, 2018).  
The extracts of the plant Cannabis sativa (marijuana) have long been used for medicinal 
purposes to treat ailments such as cramp and provide pain relief (Mechoulam, 1986; Pertwee, 
2009). However, only in the mid-1900s was the first cannabis constituent discovered, i.e., 
delta-9-tetrahydrocannabinol (Δ9-THC), which is the main psychoactive phytocannabinoid of 
the C. sativa (Gaoni and Mechoulam, 1964). Then followed the discovery of the first 
cannabinoid receptor, now referred as CB1 (Matsuda et al., 1990). Its identification and 
successful cloning then led to the discovery of the second cannabinoid receptor, CB2, and the 
first ‘endocannabinoid’ N-arachidonoylethanolamine (anandamide; AEA) (Devane et al., 
1992; Munro et al., 1993). This was followed shortly by the discovery of the second 
endocannabinoid 2-arachidonoyl glycerol (2-AG) (Sugiura et al., 1995; Mechoulam et al., 
1995).  
The ‘endocannabinoids’ are named as such because mammalian tissues are capable of 
producing their own cannabinoids on demand, which are released and bind to cannabinoid 
receptors to elicit a response. It is noteworthy that although these first two endocannabinoids 
(AEA and 2-AG) bind to CB1 and CB2, they possess distinctive properties such that 2-AG is 
a full agonist of both receptors with moderate to low binding affinity, whereas AEA is a 
partial agonist of CB1 with high binding affinity but has almost no binding affinity for CB2 
(Pertwee et al., 2010). In addition, these agonists also induce activation of numerous non-CB 
receptors. For example, AEA can bind to the transient receptor potential channel vanilloid 1 
(TRPV1), Dopamine, peroxisome proliferator-activated receptor (i.e. PPARα and PPARγ), 
and various other orphan G protein coupled receptors (e.g. GPR55) (Zygmunt et al., 1999; 
Ahluwalia et al., 2003a; Pertwee et al., 2010; Lee et al., 2016). Thus, in addition to the main 
CB receptors, cannabinoids are capable of binding to more than one receptor, depending on 
cell types and site of actions, which results in the broad activation of signaling pathways.  
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During endocannabinoid retrograde signaling, the endocannabinoids AEA and 2-AG are 
synthesized on demand in response to an increased intracellular Ca2+ concentration and 
which are then degraded after activation of the CB1 and other non-CB targets (Katona and 
Freund, 2008) (Figure 1.1). Generally, AEA is synthesized from N-acyl-
phosphotidylethanolamine (NAPE) by the enzyme NAPE-specific phospholipase D (NAPE-
PLD) (Okamoto et al., 2004). On the other hand, 2-AG is synthesized from diacylglycerol 
(DAG) by two of the DAG lipases - DAGLα and DAGLβ (Murataeva et al., 2014). Once 
transported to the site of action and taken up by the cells, fatty acid amide hydrolase (FAAH) 
catabolized AEA into free arachidonic acid (AA) and ethanolamine, whereas 2-AG is 
degraded to AA and glycerol by monoacylglycerol lipase (MAGL). Catalysis of AEA and 2-
AG sometimes involves the oxidative enzymes such as cyclooxygenase-2 (COX2) and other 
































Figure 1.1: Simplified schematic representation of endocannabinoid retrograde signaling in 
synaptic transmission, as an example of an endocannabinoid system; comprised of the 
cannabinoid receptor (in this case CB1), cannabinoid ligands (AEA and 2-AG), and their 
metabolic enzymes (NAPE-PLD, FAAH, DAGL, MAGL) (Zou and Kumar, 2018).  
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In the past few decades the study of the endocannabinoid system has gained more attention 
due to the promising therapeutic effects of the agonists on various diseases including cancer, 
Parkinson’s, epilepsy and many more (Hill et al., 2012; Patil et al., 2015). The extensive 
study of the ECS has demonstrated that cannabinoid receptor agonists induce the activation 
of non-CB receptors, and at the same time, CB receptors can be activated by wide array of 
ligands. This indicates that the ECS is involved in broad modulatory functions and also plays 
a significant role in sustaining life, and therefore the understanding of this system may lead to 
uncovering many further therapeutic treatments.  
1.2. The main cannabinoid ligands 
 
There are many ligands involved in the activation and inhibition of the endocannabinoid 
system, including the endo-, synthetic- and exogenous cannabinoids. The endocannabinoid 
and endocannabinoid-like compounds are classified based on their acyl chain: 1) N-
acylethanolamines (NAEs); 2) monoacylglycerols (MAGs); 3) N-acyldopamines; 4) N-
acylserotonin, 5) Fatty acids amides of amino acids (FAAAs), and 6) COX2-derivatives 
(Piscitelli, 2015).  
 
AEA, is a long-chain fatty acid ethanolamine and a representative of the NAEs. Other 
members of the NAEs include N-palmitoylethanolamide (PEA), N-oleoylethanolamide 
(OEA), N-stearoylethanolamide (SEA), and N-linoleoylethanolamide (LEA) (Figure 1.2). 
Although AEA is the most studied NAE, due to its activity and well characterized interaction 
with the cannabinoid receptors, it should be noted that AEA is only a minor component of 
NAEs whereas other NAEs, particularly OEA and PEA, are more abundant in animal tissues 
(Piscitelli, 2015). And, unlike AEA, OEA and PEA are better characterized as agonists of the 
PPARα receptor where OEA is often associated with satiety and feeding behaviour, while 
both OEA and PEA serve as anti-inflammatory and neuroprotective compounds (Suardíaz et 
al., 2007; Fu et al., 2003; Di Cesare Mannelli et al., 2013). However, evidence exists that 
PEA interact with the CB2 receptor although at a much lower affinity compared to PPARα 
(Facci et al., 1995) and that NAEs, particularly OEA, are capable of activating several other 































The phytocannabinoid THC was the first cannabinoid compound identified from C. sativa 
and has long been used for medicinal and recreation purposes. Over 85 phytocannabinoids 
have been identified from the same plant, but the psychoactive THC and its non-psychoactive 
isomer, cannabidiol (CBD) still remain the most studied phytocannabinoids (El-Alfy et al., 
2010; Bih et al., 2015). CBD targets both the CB1 and CB2 receptors but with lower affinity 
compared to THC (Pertwee et al., 2010), it is more likely that CBD acts as antagonist at 
CB1/CB2 rather than an agonist (Pertwee, 2008; Bih et al., 2015). Moreover, many studies 
have demonstrated that CBD can also target non-CB receptors such as GPR55, PPARγ, 
TRPV1 and those for adenosine and serotonin (Bih et al., 2015). 
 
1.3. The metabolizing enzymes 
 
The metabolism of the two major endocannabinoids, AEA and 2-AG, are welled known in 
humans with AEA and 2-AG being synthesized with the aid of enzymes NAPE-PLD and 
 
 
Figure 1.2: Structure of endocannabinoid-like compounds, N-acylethanolamides: N-arachidonoyl 
ethanolamide (AEA); N-linoleoylethanolamide (LEA); N-oleoylethanolamide (OEA); N-
stearoylethanolamide (SEA); N-palmitoylethanolamide (PEA) (Leishman and Bradshaw, 2015). 
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DAGL/, respectively and hydrolyzed by FAAH and MAGL, respectively (see Figure 1.1). 
However, multiple studies have shown that there is more than one distinct pathway involved 
in the synthesis and degradation of these endocannabinoids (Kano et al., 2009). 
 
1.3.1. Biosynthesising enzymes 
 
AEA, and its closely related long-chain NAEs, are synthesised from NAPE with the aid of 
the enzyme NAPE-PLD. NAPE plays a crucial role as a precursor in NAEs synthesis and can 
be synthesised from phosphatidylethanolamine (PE) or sn-1-arachidonate of phospholipids by 
the enzyme N-acyltransferase (NAT) (Iannotti et al., 2016). 
 
Studies of NAEs biosynthesising pathway suggested that they can be synthesised via 3 main 
routes: 1) direct hydrolysis of NAPE by NAPE-PLD; 2) a three-step catalysis, through NAPE 
deacylation to glycerophosphoethanolamine (GP-NAE) by /-hydrolase-4 (ABH4) and 
further to NAE by glycerophosphodiesterase-1 (GDE-1); and 3) a two-step pathway through 
hydrolysis of NAPE by phospholipase C, forming phospho-NAE as an intermediate and 
further dephosphorylate by a poorly characterised phosphatase (e.g. PTPN22) to NAE 
(Figure 1.3) (Kleberg et al., 2014; Iannotti et al., 2016). It was also suggested that preference 
for one pathway over another might also relate to cell/tissue specification and/or the 
availability of precursors (Muccioli, 2010).  
 
In the case of 2-acylglycerols (2-AcG) such as 2-AG, these are generally formed as an 
intermediate in the synthesis of triacylglycerol and phospholipids in the central nervous 
system (CNS) and peripheral cells (Kleberg et al., 2014). 2-AcG is known to be produced in a 
stimulus-dependent manner, activating Gq/11-coupled-receptor (e.g. glutamate receptor) as a 
result of a strong Ca2+ influx, thus upregulating 2-AG production (Muccioli, 2010).  
 
Biochemical studies have revealed two primary pathways for 2-AG production. The first one 
involves the combination of the enzymes phospholipase C (PLC) and diacylglycerol lipase 
(DAGL). Initially, PLC hydrolyses membrane phospholipids such as phosphatidylinositol, 
producing 1-acyl-2-arachidonylglycerol (diacylglycerol, or DAG) which is subsequently 
hydrolyses to 2-AG by either of the two specific enzymes DAG lipase  or  (Figure 1.3) 





































Besides the formation of DAG as a precursor, 2-AG can also be generated in an alternative 
pathway featuring a 2-arachidonoyl-lysophophatidylinositol (Lyso-PI) intermediate. This 
involves the sequential reactions of phospholipids by phospholipase A1 (PLA1), producing 
lyso-Pl intermediate, and lyso-PLC specific enzyme, producing 2-AG (Muccioli, 2010). 
Biosynthetic pathways for 2-AG are also considered to vary depending on a cell/tissue type 
and conditions of stimuli (Kano et al., 2009).   
 
1.3.2. Catalysing enzymes 
 
Degradation of endocannabinoids are categorised into two different pathways, hydrolysis and 
oxidation. The enzymes involved in the hydrolysis pathway include fatty acid amide 
hydrolase (FAAH) for NAEs and monoacylglycerol lipase (MAGL) for 2-AcGs (Kano et al., 
2009). The oxidation pathway involves the well-known oxidative enzymes cyclooxygenase 
 
 
Figure 1.3: The biosynthesis and degradation pathways of NAEs and 2-AcG using AEA 





(COX) and lipoxygenase (LOX), which regulate oxidation of many arachidonic moieties of 
endocannabinoids (Kano et al., 2009). 
 
Hydrolysis: FAAH is the primary enzyme responsible for NAEs catalysis, resulting in the 
free fatty acid and ethanolamide (Figure 1.3). Decreased levels of FAAH via enzyme 
inhibition or FAAH knock out mice result in the accumulation of NAEs (Cravatt et al., 2001; 
Kleberg et al., 2014). FAAH is found in both the CNS and the periphery (Cravatt et al., 1996) 
and is an integral membrane enzyme, with a molecular mass of ~63 kDa in human, rat, and 
mouse cells (Giang and Cravatt, 1997; Kano et al., 2009). This serine hydrolase has an 
optimum alkaline pH and is able to recognise a variety of fatty acid amides, however its 
preferred substrate is AEA, followed by LEA and OEA. It has also been reported that FAAH 
can catalyse the hydrolysis of the ester bond of 2-AG in vitro (Di Marzo et al., 1998; 
Goparaju et al., 1998; Kano et al., 2009). 
  
A second membrane-associated FAAH was identified in humans and primates, but not in 
rodent tissues (Wei et al., 2006). This was named ‘FAAH-2’. Although both FAAHs share a 
common Ser-Ser-Lys catalytic triad, they only share sequence homology of ~20% and 
FAAH-2 only contains 524 amino acids, weighs 57.4 kDa, and is localised in cytosolic lipid 
droplets rather than the endoplasmic reticulum (Wei et al., 2006; Kaczocha et al., 2010). 
Although FAAH-2 is highly expressed throughout the periphery it is less active at 
hydrolysing NAEs, compared to FAAH (Kaczocha et al., 2010). Thus, it was suggested that 
FAAH-2 might only act as a ‘rescue’ enzyme in NAE hydrolysis in a decreased/inhibited 
FAAH condition (Kaczocha et al., 2010).  
 
The third NAE-hydrolysing enzyme is the N-acyl ethanolamine-hydrolysing acid amidase 
(NAAA). In contrast to FAAH, NAAA is a member of cysteine hydrolase family, which 
preferentially hydrolyses PEA, with an optima at acidic pH (4.5-5) and being localised in the 
lysozymes (Iannotti et al., 2016). High levels of NAAA expression are seen in the immune 
cells, specifically macrophage, where its level can increase during inflammation in response 
to increased PEA levels (as anti-inflammation) (Iannotti et al., 2016). 
 
MAGL is recognised as the main enzyme in 2-AcG degradation, hydrolysing acylglycerols to 
free fatty acids and glycerol (Iannotti et al., 2016). Human, rat, and mouse MAGL all contain 
303 amino acids and weigh 33 kDa (Karlsson et al., 1997, 2001; Dinh et al., 2002a). A study 
of 2-AG hydrolysis in mouse brain homogenate clearly shows that MAGL is responsible for 
 17 
~85% of 2-AG catalysis whereas the other 15% is catalysed by poorly characterised 
hydrolases, ABH6 and ABH12 (Blankman et al., 2007).  
 
Oxidation: In a less common degradation route, both NAEs and 2-AcGs can be oxygenated 
by both COX and LOX. In mammalian systems, there are 3 forms of COX: COX-1, COX-2, 
and COX-3 (Kano et al., 2009). Incubation of AEA with these enzymes showed that purified 
COX-2, catalysed both 2-AG and AEA, as efficacious and with lower affinity compared to 
AA (Wilson et al., 2001). For LOX, this lipoxygenase is expressed in both mammals and 
plants. Several types of LOXs display active oxidation on the arachidonate positions of 
endocannabinoids, both AEA and 2-AG, producing various types of hydroxyeicosatetraenoic 
acid (HETE) (Rouzer and Marnett, 2011).  
 
1.4. The Main Cannabinoid receptors – CB and Non-CB  
 
1.4.1. Cannabinoid receptors: CB1 and CB2 
 
The two cannabinoid receptors in mammalian systems, CB1 and CB2, are both primary 
mediators of most endocannabinoids as well as other exogenous cannabinoid ligands (e.g. 
THC and CBD). CB1 is found throughout the central nervous system (CNS), with high 
expression in the hippocampus, olfactory bulb, basal ganglia, and cerebellum, where it is 
involved in retrograde signaling of endocannabinoids (Castillo et al., 2012). Research has 
revealed that progressive loss of CB1 is an early sign for Huntington’s disease (HD) and the 
worsening of the disease in an already HD patient (Blázquez et al., 2010). Although CB1 is 
most abundant in the brain it can also be found in synaptic nerves, cardiac muscle, adrenal 
gland, ovary, testes, immune cells, as well as the GI tract where CB1 participates in the 
regulation of food intake and energy balance (Zou and Kumar, 2018).  
 
CB2 is often referred to as ‘the peripheral CB receptor’ because of its relatively low 
expression in the CNS. CB2 is predominantly found in immune cells particularly 
macrophages, and in other peripheral tissues and organs including bone, adipose tissue, liver, 
GI tract, reproductive and cardiovascular system (Zou and Kumar, 2018). CB2 is also 
expressed by some neurons both in the brain and peripheral sites (Onaivi et al., 2006). 
Despite the low expression of CB2, increased expression in the CNS was observed following 
tissue injury or inflammation, but the mode of action remains unclear (Maresz et al., 2005). 
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Both CB1 and CB2 are members of the superfamily of G protein-coupled receptor proteins 
(GCPR), and are coupled to G protein Gi and Go (Lu and Mackie, 2016). Their activation 
results in, (i) the inhibition of adenylyl cyclase (AC) and voltage gated calcium channels, (ii) 
down regulation of cyclic AMP (cAMP), (iii) activation of the mitogen-activated protein 
kinase (MAPK), (iv) activation of Phosphoinositide 3-kinase (PI3K) pathway and (v) various 
other signaling pathways depending on the specific cell type (Lu and Mackie, 2016; Zou and 
Kumar, 2018). These receptors exert a broad neuromodulatory function, both in the 
peripheral and CNS, as well as in non-neuronal cells, in a cell type and ligand specific 
manner with different ligands having different selectivities and affinities for the receptors and 
thus exerting distinct signaling cascades (Lu and Mackie, 2016; Zou and Kumar, 2018). 
Studies have shown that cannabinoid receptors can be activated by endo- and exogenous 
ligands, including synthetic ligands such as WIN 55, 212-2 (Pertwee et al., 2010).  
 
1.4.2. Non-CB receptors 
1.4.2.1. TRPV1 
 
The transient receptor potential vanilloid type 1 (TRPV1) belongs to the transient receptor 
potential (TRP) superfamily and its natural ligand is capsaicin, the natural compound found 
in chili pepper (Caterina et al., 1997). TRPV1 is involved in temperature sensing, pain and 
nociception (Caterina et al., 2000). This receptor is primarily expressed in sensory neurons 
where it can be activated by stimuli such as temperature change (>43°C), acidity (pH<6.9), or 
various other toxins (Pertwee et al., 2010).  
In sensory neurons, TRPV1 co-localizes with CB1 and CB2, making intracellular cross-talk 
between several types of receptor possible (Zou and Kumar, 2018). Although AEA is an 
agonist of CB1 and CB2, under certain condition (such as during synaptic transmission and 
pain regulation, when CB1 is expressed at low levels), AEA can act as a full agonist for 
TRPV1 (Zou and Kumar, 2018). In addition, several other endocannabinoids such as noladin 
ether, virodhamine, N-arachidonoyl dopamine (NADA), but not 2-AG, can all act as full 
agonists of TRPV1 (Starowiczet al., 2007). Evidence also exists for endocannabinoid-like 
compounds such as OEA and CBD exerting full agonist activity upon interaction with 
TRPV1, where CBD binds to TPRV1 almost with the same Ki as with capsaicin (Bisogno et 
al., 2001). On the other hand, OEA activates TPRV1 and initiates vagal neurosensory nerves 
excitation in the nervous control of food intake, and also inhibits intracellular Ca2+ uptake in 
cells expressing TRPV1 (Thabuis et al., 2008). The interaction of TRPV1 with wider 
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endocannabinoid and endocannabinoid-like compounds suggests its strong association with 
the ECS. 
1.4.2.2. GPR55 and deorphanized GPRs 
 
Both CB1 and CB2 belong to a family of Class A GPCRs and cannabinoid receptor agonists 
can therefore also act at other GPCRs, mainly deorphanized GPR55, GPR119, GPR3, GPR6, 
and GPR12 (Pertwee et al., 2010). Research is currently proposing that deorphanized GPCR 
is a third true cannabinoid receptor, with the most-likely candidate being GPR55 (Morales 
and Reggio, 2017) because it is targeted by wide variety of cannabinoids including 
endogenous, phytogenic, as well as synthetic cannabinoids (Pertwee et al., 2010). GPR55 is 
widely expressed in the brain and the peripheral site, with particularly high expression in the 
striatum; co-localising with CB1 and CB2 (Sawzdargo at al., 1999).  
 
Although AEA targets both CB1 and CB2, with slightly higher affinity for CB1 compared to 
CB2, it has an even higher affinity for GPR55 compared to CB1 (Ryberg et al., 2007). This 
study also demonstrated that 2-AG and THC are agonists for GPR55 while CBD is an 
antagonist (Ryberg et al., 2007). Despite being the target for many cannabinoid ligands, 
GPR55 displays low sequence identity to both CB1 (13.5%) and CB2 (14.4%) (Pertwee et al., 
2010).  
 
GPR3, GPR6, and GPR12 are three orphan Class A GPCRs that are mainly expressed in the 
CNS and involved in mediation of β-arrestin2 recruitment (Pertwee et al., 2010). They 
exhibit close phylogenetic relationship with cannabinoid receptors, melanocortin receptors 
(MCRs), lysophospholipid receptors, adenosine receptors (AR), and the GPR3/6/12 subset, 
forming the so-called MECA cluster (Uhlenbrock et al., 2002; Morales et al., 2018). Very 
little is known about their ligands. AEA and 2-AG display no significant activity at these 
orphan receptors, whereas CBD demonstrates activity at GPR3, GPR6 and GPR12 (Brown et 
al., 2017; Laun and Song, 2017). CBD acts as an inverse agonist to inhibit β-arrestin2 
recruitment on GPR3, GPR6, and GPR12. This suggests that CBD may act as potential 
neuroprotective agent for Alzheimer’s and Parkinson’s disease by acting on these GPCRs 
(Brown et al., 2017; Laun and Song, 2017).  
 
GPR119 is primarily expressed in the pancreatic and GI tract, and is involved in the 
regulation of insulin secretion (Soga et al., 2005). Although GPR119 is phylogenetically 
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related to cannabinoid receptors, it is only activated by fatty acid amides, including AEA, 
OEA and PEA, with OEA being the most efficacious (Overton et al., 2006). Despite GPR119 
being closely related to cannabinoid receptors, only N-oleoyl dopamine and OEA display 
high affinity for GPR119 (Overton et al., 2006), and both of these ligands do not interact with 




Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription 
factors belonging to the nuclear hormone receptor superfamily, all sharing close structural 
homology (Tsai and O'Malley, 1994). In mammals, PPARs exist in three isoforms (, /, 
and ). PPARs were first identified in 1990 and are associated with the regulation of diverse 
physiological and pathophysiological processes, notably lipid and glucose metabolism, 
inflammation, cell differentiation, and energy homeostasis (Issemann and Green, 1990; 
Cooper, 2000; Grygiel-Górniak, 2014).  
In the nucleus, inactivated PPAR is associated to a co-repressor. The classic pathway through 
which PPAR activation occurs is through the formation of heterodimer complex with another 
nuclear hormone receptor, the retinoid X-receptor (RXR) (Grygiel-Górniak, 2014). The 
ligand then binds to this heterodimer, causing a conformational change in the PPAR structure 
and dissociation of the co-repressor and the recruitment of co-activator, simultaneously 
(Grygiel-Górniak, 2014). Activation and suppression of PPAR is modulated depending on the 
specific ligand binding to PPAR-RXR heterodimer as the exchange of co-repressor and co-
activator occurs (Figure 1.4) (Grygiel-Górniak, 2014). Activated PPAR complex binds to 
peroxisome proliferator-response elements (PPREs) located on the regulatory regions of the 
target genes and carries out mRNA transcription (Chinetti-Gbaguidi and Staels, 2009; 
Grygiel-Górniak, 2014).  
 
PPARs have large ligand binding domains which can be activated by various types of 
lipophilic ligands including synthetic compounds and plant extracts (O'Sullivan, 2016). 
Cannabinoids can activate PPAR through a few mechanisms: 1) direct binding of 
cannabinoids to PPAR, 2) indirect binding through the conversion of cannabinoid into PPAR-
active metabolites, or 3) activation of cannabinoid cell surface membrane receptor which 
results in PPAR activation through, yet, an unclear cell signaling cascade (O'Sullivan, 2007). 
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Another possible activation mechanism suggested the active translocation of cannabinoids to 








Ligands binding to FABPs have been shown to promote nuclear localization and PPAR 
interaction (Kaczocha et al., 2012; Hughes et al., 2015). Specifically, binding to FABP1 and 
FABP2 promotes nuclear localization and the activation of PPARα (Hughes et al., 2015). 
Conversely, FABP5 acts as an intracellular carrier mediating the nuclear translocation of 
OEA and reduces PPARα activation (Kaczocha et al., 2012). In addition, localization of AEA 
from plasma membrane to FAAH (for hydrolysis) was shown to be transported by FABP5 
and FABP7 (Kaczocha et al., 2009). This catabolism was found to be inhibited by THC and 
CBD as the phytocannabinoids competed for FABP (Elmes et al., 2015). 
The endogenous PPAR activators are a wide class of bioactive lipids which include 
endocannabinoids, phytocannabinoid, and synthetic cannabinoid ligands (O'Sullivan, 2016). 
AEA can activate PPARα and this induces neuroprotective properties (Sun et al., 2007). 
Similarly, 2-AG can activate PPARα, independent of CB1 and CB2 (Kozak et al., 2002). 
There is also strong evidence that OEA and PEA act as PPAR agonists, specifically 
activating PPARα which affects various physiological and pathophysiological functions, 
notably feeding and anti-inflammatory pain (Suardíaz et al., 2007; O'Sullivan, 2016). Apart 
from PPARα activation, although with less evidence, studies have also shown that OEA, 
PEA, AEA and 2-AG are able to activate PPAR (O'Sullivan, 2016).   
The phytocannabinoids and their derivatives, including THC and CBD, do not bind to 
PPARα but rather activate PPAR (O'Sullivan, 2016). Synthetic cannabinoids, 
 
 
Figure 1.4: Schematic representation of the PPAR structure and its transcription mechanism 
(Grygiel-Górniak, 2014). PPAR activation occurs through initial binding of the ligand and 
heterodimerization with RXR, resulting in a conformational change, where the co-repressor is 
exchanged with the recruitment of a co-activator. This active PPAR transcription complex then 
binds to the DNA response element, the PPRE, located in the promoter region, and thus regulates 
transcription of the target gene. 
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Thiazolidinedione (glitazones) compounds, a family of drugs used for Type 2 diabetes 
treatment, are also common PPAR agonists, particularly Rosiglitazone, which has high 
affinity and specificity for this PPAR (Lehmann et al., 1995). 
Only the break down products of endocannabinoids, especially of the NAEs, have been found 
to act as natural agonists of PPARβ/δ. For example, arachidonic acid (AA) from AEA (Yu et 
al., 2014), and oleamide derived from OEA (Dionisi et al., 2012), bind and increase 
transcriptional activity of PPARβ/δ (O'Sullivan, 2016). However, a synthetic agonist has 
been chemically produced (GW0742) which selectively binds to PPARβ/δ (Sznaidman et al. 
2003) and which was used in the current study. 
PPAR activation can therefore be achieved with phytocannabinoids, endocannabinoids and 
their derivatives, and synthetic endocannabinoid-like compounds.  
1.5. Evidence for an endocannabinoid system in singled cell eukaryotes 
 
The first suggestions for the existence of an ECS in single celled organisms were made in the 
1970’s. Bram (1976) first showed that THC and cannabinol affected the cell morphology of 
the slime mould Dictyostelium discoideum, with cells becoming round and immobile. Cells 
recovered within a few hours (time not stated) after THC treatment but not with cannabinol. 
In the same year, McClean and Zimmerman (1976) showed that THC caused the cells of the 
ciliate Tetrahymena pyriformis to become round and move in a sluggish manner; once again 
recovering after some hours (time not stated). THC also caused a delay in cell division in this 
ciliate, which was dose dependent, and with cells being most sensitive in their G2 phase of 
cell division (Zimmerman et al., 1981). 
  
Pringle et al. (1979) found that THC reduced the population growth of the amoeba-flagellate 
Naegleria fowleri and prevented transformation of trophozoites into cysts or flagellates, but 
there was no effect on cell shape and movement. A reduction in population growth was also 
reported for three other amoebae, Acanthamoeba castellanii, Vermamoeba (Hartmannella) 
vermiformis, and Willaertia magna when treated with AEA and 2-O-acylglycerol (2-O-AG) 
(Dey et al., 2010). This study also showed that it was the cannabinoid itself, and not a 
breakdown product, that elicited this response with comparable population survival being 
achieved with 2-O-AG and 2-O-AG ether, a nonhydrolyzable analog of 2-O-AG. Whilst all 
four amoebae are in very different taxonomic groups (N. fowleri and W. magna are members 
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of the sub-phylum Percolozoa, while V. vermiformis and A. castellanii are members of the 
sub-phylum Lobosa), all were affected by cannabinoids in a similar manner.  
  
This ability to perceive and response to exogenous endocannabinoids led to the search for N-
acylethanolamines and their metabolic enzymes in these cells. NAEs were first identified in 
the yeast Saccharomyces cerevisiae along with its phospholipid precursors NAPEs and 
biosynthesizing NAPE-PLD-like enzyme (Merkel et al., 2005). Then, a suite of 
endocannabinoids (particularly NAEs) were reported in Tetrahymena thermophila 
(Anagnostopoulos et al. 2010) and D. discoideum (Hayes et al., 2013). The hydrolyzing 
enzymes FAAH and MAGL were reported in more organisms, mainly protists, these included 
D. discoideum, T. pyriformis, T. thermophila, Plasmodium falciparum, and the yeast S. 
cerevisiae (Karava et al., 2001, 2005; McPartland et al., 2006; Evagorou et al., 2010). 
 
Since most data available for the evidence of a presence of ECS in unicellular eukaryotes is 
in the ciliate Tetrahymena, it is worth investigating the system in this ciliate further.  
 
1.6. The endocannabinoid system in the ciliate Tetrahymena  
 
1.6.1. The endocannabinoid ligand 
 
The presence of a suite of endocannabinoids has been found in the cells of T. thermophila 
(Anagnostopoulos et al., 2010). This study reported the presence of: 1) N-acylethanolamines 
(NAEs); 2) 2-acylglycerols (2-AcGs); and 3) Free fatty acids (FFAs).  
The 6 main NAEs, in order of abundance, were N--linolenoylethanolamine (GLEA), N-
eicosenoylethanolamine (EEA), N-linoleoylethanolamine (LEA), N-palmitoylethanolamine 
(PEA), N-oleoylethanolamine (OEA) and N-stearoylethanolamine (SEA). A few other 
NAEs, including AEA, were also identified, but these were present at a very low 
concentration (Anagnostopoulos et al., 2010). Although GLEA is present at the highest 
concentration it is not common in nature (Anagnostopoulos et al., 2010). SEA is present at a 
very low concentrations compared to other NAEs in both the human and Tetrahymena 
systems (Anagnostopoulos et al., 2010; Kleberg at al., 2014). EEA can only be found in a 
traceable amount in the human milk and its specific function has not been characterised 
(Gaitán et al., 2018). LEA on the other hand, is more common and can be found primarily in 
the GI tract, alongside with PEA and OEA (Artmann et al., 2008) where all three NAEs 
exhibit similar anorexic and pharmacological functions, activating more or less at the same 
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receptors, mainly PPARs (⍺ and γ) and TRPV1, and serving a crucial role in the regulation of 
food intake and anti-inflammatory effects (Kleberg et al., 2014). 
2-AcGs corresponding to their respective NAE were 2-AcG: 2-γ-linolenoylglycerol (2-GLG), 
2-eicosenoylglycerol (2-EG), 2-linoleoylglycerol (2-LG), 2-palmitoylglycerol (2-PG), and 2-
oleoylglycerol (2-OG), but not 2-stearoylglycerol (2-SG). Again, 2-AG was also detected, but 
at much lower concentration compared to other 2-AcGs (Anagnostopoulos et al., 2010). 
The free fatty acids arachidonic (AA), linoleic (LA), and γ-linolenic (GLA), were detected at 
sufficient concentrations, with GLA being dominant followed by LA and AA, whereas other 
FFAs (e.g. eicosapentaenoicacid [EPA] and docosahexaenoic [DHA]) were below the 
detection limit (Anagnostopoulos et al., 2010). FFAs predominated over 2-AGs and NAEs, 
by one to three orders of magnitude.  
Anagnostopoulos et al. (2010) also tested for the substrate of FAAH enzymes using AEA, 
LEA, ALEA (N-α-linolenoylethanolamine, analog of LEA), and GHLEA (N-γ-
homolinolenoylethanolamine, analog of GLEA). All NAEs were hydrolyzed by FAAH with 
the highest enzyme activity being evident with AEA, followed by LEA, ALEA and GHLEA. 
This suggests that AEA, although present at low abundance, is the best endogenous substrate 
for FAAH in T. thermophila (Anagnostopoulos et al., 2010). 
Anagnostopoulos et al. (2010) also showed that there was a fluctuation of NAE, 2-AcG, and 
FFA concentrations at different cultivation temperatures; at higher temperature (33°C) NAEs 
significantly increased whereas FFAs and 2-AcGs decreased (Anagnostopoulos et al., 2010). 
Thus, it was suggested that NAEs may play a role in membrane fluidity and cellular 
protection in a changing environment as well as in food intake and development. The 
function of NAEs was not investigated further, however the authors stated that preliminary 
experiments showed that most NAEs affected the growth of T. thermophila (but no mention 
of positive/negative effects) (Anagnostopoulos et al., 2010). 
1.6.2. Enzymes 
The two main degrading enzymes, but not the synthesizing enzymes, of the endocannabinoid 
system have been reported to exist in Tetrahymena., FAAH (the NAE hydrolase) was 
reported in both T. pyriformis (Karava et al., 2001, 2005) and T. thermophila (McPartland et 
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al., 2006), whereas, MAGL (the 2-AcG hydrolase) was reported in T. thermophila 
(McPartland et al., 2006; Evagorou et al., 2010).  
 
1.6.2.1. FAAH 
Karava et al. (2001) were the first to identify membrane-bound FAAH-like activity in T. 
pyriformis. The authors demonstrated that AEA was taken up by intact T. pyriformis cell and 
was rapidly metabolized to mixed free fatty acids comprising of phospholipids (PL) (70%), 
neutral lipids (NLs) (20%), and free AA (6%), in descending order of cytosolic concentration 
(Karava et al., 2001). The presence of AA at almost undetectable level in T. pyriformis 
correlated with the study of Anagnostopoulos et al. (2010). Amide hydrolysis activity was 
also detected in the culture medium where almost 80% of AEA was catalyzed to free AA. 
The amidohydrolase was found to be specific for AEA within the cell, but once secreted it 
could also hydrolyse NAEs other than AEA, e.g., OEA and PEA (Karava et al., 2001).   
The optimum pH for the amide hydrolase in T. pyriformis was pH 9-10, which is similar to 
FAAH activity reported in variety of tissues and cell types (Karava et al., 2001; Wei et al., 
2006). It is a serine hydrolase, which does not depend on Ca2+, Mg2+, or sulfhydryl group for 
its enzymatic activity on AEA (Karava et al., 2001& 2005); also similar to the FAAH in 
various mammalian tissues and cell lines (Desarnaud et al., 1995; Maccarrone et al., 1998; 
Karava et al., 2001). Moreover, Karava et al. (2005) revealed the presence of 2 isoforms of 
FAAH in T. pyriformis: a 66 kDa (non-microsomal fraction) and a 45 kDa (in the cytosol). 
Interestingly, the 66 kDa isoform is close in size to that reported for human and mammalian 
FAAH (63 or 67 kDa) (Giang and Cravatt, 1997; Maccarrone et al., 1998). The 45 kDa on the 
other hand, is close to the 46 kDa of amide hydrolase in invertebrates (Matias et al., 2001).  
1.6.2.2. MAGL  
 
Using Blast and phylogenetic tree comparisons of the human and ciliate genomes, MAGL, 
which catalyze the breakdown of 2-AG was believed to be present in T. thermophila 
(McPartland et al., 2006). Its presence was confirmed experimentally four years later when it 
was found to be involved in the catalysis of 2-AG and other 2-AcGs in T. thermophila 
(Evagorou et al., 2010). In mammalian systems, the catalysis of 2-AcG involves the action of 
both MAGL and FAAH (see section 1.3.2) and this was also recorded for T. thermophila 
(Evagorou et al., 2010). It was also shown that 2-AG hydrolysis was pH and temperature 
dependent, exhibiting optimum pH at 8-9 and 37-40 °C (Evagorou et al., 2010).  
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Two isoforms of MAGL were found in T. thermophila; cytosolic (40 kDa) and membrane-
bound (45 kDa) with the activity of the latter being twofold higher than the former (Evagorou 
et al., 2010). Two isoforms of MAGL have also been reported for several cell types (Bisogno 
et al., 1997; Dinh et al. 2002a).  
 
1.6.3. The potential endocannabinoid receptor in Tetrahymena 
 
A study of functional orthologs of endocannabinoid proteins, by phylogenetic tree analysis 
and functional mapping, showed that the main endocannabinoids receptors CB1, CB2, 
TRPV1, and GPR55 were absent from T. thermophila (McPartland et al. 2006). However, 
there are a few suggested (lesser-known) targets that are known to interact with NAEs, which 
might be the targets in T. thermophila (Table 1.1). Those that the current study deemed 




Receptor Binds NAEs Binds other 
cannabinoids 
Presence in Tetrahymena 
CB1 AEA
















PEA a,c, LEA a,c, 
No Possibly - GPR119 mainly interact 
with acid amides 
GPR3/6/12 AEA
 a 2-AG a, CBD a Possibly - GPR6 was reported as 
chemo sensory receptor in T. 
thermophila d 
Opoid No
 a CBD a, THC a Yes - µ subunit e 
Glycine AEA
 a 2-AG a, THC a, 
CBD a 
Possibly - essential in chemotaxis  
Serotonin (5-HT) AEA
 a CBD a Yes f 
Dopamine AEA
 a CBD a, THC a Yes - a present of at least D1 g 
PPARs AEA
a,c, OEAa,c, 
PEA a,c, LEA a,c, 
SEA a,c 
2-AG a,c, CBD a,c, 
THC a,c, 
WIN55212 a 
Possibly – A presence of 
peroxisomes h 
Table 1.1: A list of receptors known to interact with cannabinoids and their presence/absence in 
Tetrahymena. a Pertwee et al., 2010; b McPartland et al., 2006; c Kleberg et al., 2014; d Lampert et al., 
2011; e Chisa et al., 1993; f Ciliate.org, 2019; g Ud-Daula et al., 2012; h De Duve and Baudhuin, 1966 
 27 
1.6.3.1. The case of PPARs 
 
In mammalian systems, endocannabinoids and most NAEs are known to interact with 
PPARs, acting as both agonists and antagonists (O'Sullivan, 2016). From the list of NAEs, 
within T. thermophila (Section 1.6.1), with the exception of GLEA and EEA, all can target at 
least one PPAR isoform (Kleberg at al., 2014; O'Sullivan, 2016). T. pyriformis, although not 
yet reported to have PPAR receptors, do possess peroxisomes (De Duve and Baudhuin, 1966; 
Ciliate.org, 2019). The peroxisomes contain at least 50 different enzymes for various 
biochemical pathways; however, they are mainly involved in the oxidation of fatty acids, 
regulating the lipids biosynthesis and the major source of metabolic energy (Cooper. 2000). 
The peroxisomes in T. pyriformis are tightly associated with the mitochondria where they 
play a crucial role in the oxidation of fatty acids during gluconeogenesis, providing major 
source of metabolic energy for the ciliates (Müller et al., 1968; Hogg, 1969; Blum, 1982). 
This is similar to the role of PPAR in mammalian systems, e.g. PPAR⍺ activation by OEA 
results in lipid catabolism and homeostasis through the β-oxidation pathway. Thus, in the 
absence of the four main cannabinoid receptors, endogenous NAEs might target PPAR-like 
receptors in Tetrahymena.  
 
1.6.3.2. The case for GPCRs 
 
Another interesting receptor worth investigating is a G protein-coupled receptor (GPCR) 
because, 1) of their high percentage identical sequence homology to CB1 and CB2, sharing 
the same superfamily of 7-transmembrane receptor (7-TMR) (Morales et al., 2018); and 2) 
they are a common target of many cannabinoids including NAEs (Pertwee et al., 2010).  
 
GPR55, which interacts with many cannabinoids, has not been identified in any species of 
Tetrahymena (McPartland et al., 2006; Ciliate.org., 2019). However, homologues to GPR6 
and GPR37 have recently been identified in T. thermophila (Lampert et al., 2011; Zou and 
Hennessey, 2017). Both act as chemosensory receptors, but GPR6 responds to 
chemoattractants (Lampert et al., 2011) while GPR37 responds to chemorepellents (Zou and 
Hennessey, 2017). In mammals, both GPR6 and GPR37 are expressed in the CNS, notably in 
the brain, co-localizing with cannabinoid receptors (Alavi et al., 2018) and both are important 
regulators of the dopaminergic system, with neuroprotective effects in Parkinson’s disease 
(PD) (Alavi et al., 2018). Of the two, GPR6 is considered a potentially interesting 
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endocannabinoid target in Tetrahymena as it shares a high amino acids sequence identity 
(35%) with CB1 and CB2 (Lee et al., 2001).  
 
Sphingosine-1-phosphate (S1P) is the endogenous agonist of GPR6 in mammals (Uhlenbrock 
et al., 2002). However, further studies failed to observe specific S1P-induced responses in 
cells transfected with GPR6 (Yin et al., 2009). Thus, GPR6 is still considered an orphan 
receptor. Despite this, various endocannabinoids and phytocannabinoids have been tested for 
their capability to alter β-arrestin2 recruitment to GPR6 (Laun and Song, 2017). AEA and 2-
AG demonstrated no significant effect at altering β-arrestin2 recruitment, while amongst the 
five phytocannabinoids tested, CBD significantly reduced β-arrestin2 recruitment in a 
concentration dependent manner. This suggests that CBD is a novel inverse agonist for GPR6 
(Laun and Song, 2017). CBD has also been demonstrated to act on a variety of GCPRs. 
These include antagonising effects at CB1 and CB2 (with low affinity), GPR55, GPR18, 
inverse agonist at GPR3 (Laun and Song, 2017), and an agonist at Serotonin 5H1Ta (Bih et 
al., 2015). Nonetheless, as the presence of GPR6 (and possibly other GCPRs) has been 
confirmed in Tetrahymena, it may be possible that Tetrahymena elicits a response to 
cannabinoids through GCPRs in the absence of the four main receptors.  
 
1.6.3.3. The case for a dopamine receptor 
 
Dopamine is an essential neurotransmitter in the brain and is involved in many neuro-
modulatory roles, including the control of movement, memory and learning, cognitive, 
emotions, addiction and brain reward (Covey et al., 2017).  Dopamine is predominantly 
expressed in the brain; however, it is also found in the peripheral nervous system where it 
functions as a local paracrine messenger (e.g. hormone) and is involved in the control of wide 
physiological and pathological processes (García et al., 2015).  
 
Cannabinoids interact with the dopamine receptor both directly (Pandolfo et al., 2011) and 
also indirectly through the GABA pathway in which cannabinoid binding to the CB1 receptor 
causes an increase in dopamine release from dopaminergic neurons (Garbutt, 1983). Under 
typical conditions, dopaminergic neurons are inhibited by the activation of GABAB receptors 
(Figure 1.5A) (Oleson and Cheer, 2012). Consequently, during phasic dopamine events, such 
as when presented with a drug associated cue, intracellular Ca2+ abruptly rises, which results 
in the activation of endocannabinoid synthesizing enzymes (e.g. DAGL). This leads to the 
synthesis of endocannabinoids (e.g. 2-AG), which are released into the extra-synaptic cleft 
 29 
where they couple to the Gi/o of CB1 receptors on GABA presynaptic terminals and thus, 
GABA release is suppressed (Figure 1.5B) (Oleson and Cheer, 2012). Suppression of GABA 
disinhibits dopamine neurons, and at the same time promotes phasic dopamine events 
(Oleson and Cheer, 2012).  The dopamine released then binds to dopamine receptor to elicit a 
response. Using these pathways, the endocannabinoids are able to tune with synaptic 




































Dopamine was previously reported to be the major catecholamine in T. pyriformis (Nomura 
et al., 1998) and the presence of the D1 receptor was confirmed in T. thermophila although 
they did not rule out the presence of a D2 receptor (Ud-Daula et al., 2012). Thus, it is a 
worthy candidate for an endocannabinoid receptor in Tetrahymena. 
 
 
Figure 1.5: Shows the indirect interactions of cannabinoids and dopamine through GABAergic and 
glutamatergic terminals on dopamine neuron (Oleson and Cheer, 2012). A) Under typical conditions, 
as GABA/glutamate is active, dopamine neurons are inhibited. B) Indirect interaction occurs during 
phasic dopamine events. Where phasic dopamine results in the synthesis of endocannabinoids. These 
cannabinoids then activate CB1 on GABAergic terminals, suppressing GABA release and stops the 
inhibition of dopamine. 
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1.7. Overall objectives and specific aims  
 
Many studies have shown that the endocannabinoid system is involved in the regulation of 
many fundamental modulatory systems in both multi- and uni-cellular organisms (see 
sections 1.1–1.6). The ciliate Tetrahymena is a common model organism used in many 
biomedical studies due to its simplicity and availability of genome information (Ruehle et al., 
2016). Moreover, there is evidence for its cells possessing a suite of cannabinoids and their 
metabolising enzymes (see sections 1.6.1 and 1.6.2); but its target receptor(s) is currently 
unknown. Therefore, this study investigated three potential cannabinoid target receptor(s) in 
Tetrahymena pyriformis. 
The overall objective was to quantify and compare the lethal effect of selected PPAR 
agonists, OEA, PEA, AEA, CBD and two synthetic cannabinoids (GW0742 and 
Rosiglitazone), on T. pyriformis and to determine whether the response was elicited through a 
pathway involving PPARs, GCPRs and/or a dopamine receptor.  
The specific aims were to: 
a. Compare the MIC, IC50 and lethal doses of each agonist.  
b. Determine the longevity of the negative effect on ciliate cells. 
c. Using specific antagonists, to determine whether the blocking of certain receptors 
alleviated the negative effect of the agonists. Specifically, the following 
receptors/pathways were blocked: 
i. PPARα, PPARβ/δ and PPARγ receptors 
ii. Dopamine D2 receptor  
iii. GCPR pathway inhibitors:  
i. Pertussis toxin (PTX) – targets catalysis of ADP-ribosylation of Gαi/o 
ii. H89 – a Protein Kinase A inhibitor    
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2. Materials and Methods 
 
2.1 Organisms and Maintenance 
 
2.1.1. Klebsiella aerogenes 
 
The bacterium Klebsiella aerogenes (National Collection of Type Cultures [NCTC] 9528) 
was used as prey for the ciliate Tetrahymena pyriformis (Culture Collection of Algae and 
Protozoa [CCAP] 1630/1W). Streak plates of K. aerogenes were prepared on Lysogeny Broth 
(LB) agar plates (see Appendix 1) and incubated at 25C for three days. Chalkley’s medium 
(see Appendix 1) was poured onto two plates and the cells were scraped off into suspension 
using a sterile spreader. The bacterial suspension was stored at 4C.  
 
2.1.2. Tetrahymena pyriformis 
 
The ciliate was routinely cultured in 500 ml of Chalkley’s medium, supplemented with ca. 1-
2 ml of the K. aerogenes suspension, and incubated at room temperature (23C) for three 
days prior to experiments. On the day of an experiment, the T. pyriformis culture was 
concentrated by centrifuging sixteen 15 ml samples at 2000 rpm for 15 minutes. The 14 ml 
supernatants were carefully removed from each tube. The remaining 1 ml T. pyriformis 
concentrates were vortexed and combined into one tube.   
 
2.2 Cell counts 
 
2.2.1. T. pyriformis 
 
The ciliate suspension was fixed with glutaraldehyde (0.5% v/v final concentration) and 
loaded into haemocytometers. The number of cells in 36 large squares was determined using 
a light microscope (40x magnification). The average number of cells/square was multiplied 
by 1 × 104 to yield cell concentration (cells/ml). Experiments only used cultures that 
contained at least 9 × 104 cells/ml.  
 
2.2.2. K. aerogenes  
 
The bacterial suspension was diluted ten-fold down to the 10-3 dilution, using sterile distilled 
water. Each was stained with 2-3 drops of the DNA stain 4′, 6-diamidino-2-phenylindole 
(DAPI) for 15-20 minutes. The stained sample, of a known volume (and known dilution) was 
captured on a 0.2 m filter (Whatman, Micropore) using a vacuum pump. A slide was then 
prepared by (i) adding one drop of immersion oil to the slide and smearing it over the slide, 
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(ii) placing the filter on top (cells side up), (iii) adding a drop of oil to the center of the filter, 
(iv) applying a coverslip and (v) adding a final drop of oil.   
 
The slide was viewed with an epifluorescence microscope using UV excitation (cells appear 
blue). The number of cells in randomly selected Whipple grids was determined until at least 
400 cells had been counted. The average number of cells per Whipple grid was multiply by 
23,068 (as the Whipple grid is 1/23068th the area of the filter), giving the average number of 
cells captured per filter. Knowing the volume filtered, and dilution used, the number of 
cells/ml of the undiluted bacterial suspension was deduced.  
 




Six agonists were employed in this study: N-oleoylethanolamine (OEA), N-
palmitoylethanolamine (PEA), N-arachidonoylethanolamine (anandamide or AEA), 
cannabidiol (CBD), GW0742, and Rosiglitazone (all obtained from TOCRIS, Biotechne, 
UK). All were maintained as 10 mM stocks, except AEA which was at 14.4 mM, in ethanol, 
at -20C. On the day of an experiment stock solutions were diluted to 10-1 and 10-2 (e.g. 5 µL 
of 10 mM stock into 45 L Chalkley’s medium for a 10-1 dilution). For experiments, a known 
volume of agonist was added to 200 µL of T. pyriformis to obtain the desired starting 
concentration (e.g. 3 µL of a 10-1 dilution of e.g. CBD was added to 200 µL of T. pyriformis 




Three types of antagonists/blockers were used in this study (Table 2.1). The first type 
targeted PPAR receptors, i.e., GW6471 (PPAR  blocker), GSK3787 (PPAR / blocker) 
and T0070907 (PPAR  blocker) (TOCRIS, Biotechne, UK). The second type, Haloperidol 
hydrochloride, (TOCRIS, Biotechne, UK) targeted the dopamine hormone receptor. The last 
type were G protein-coupled receptor pathway inhibitors, i.e., Pertussis toxin (PTX) (target 
catalysis of ADP-ribosylation of Gαi/o) and H89 (Protein kinase A inhibitor) (TOCRIS, 
Biotechne, UK). All antagonists/blockers were maintained at 10 mM, in ethanol, at -20 C, 




Table 2.1: A summary of the antagonists/blockers used in this study, together with their 
molecular target 
 
Blocker Receptor Target  
GW 6471 PPAR⍺ 
GSK 3787 PPARβ/δ 
T0070907 PPARγ 
Haloperidol Dopamine 
Pertussis toxin G⍺i/o 





2.4.1. General response of T. pyriformis to an agonist, using CBD as an example 
 
Triplicate samples of T. pyriformis (200 µL) were treated with CBD at 0 µM, 4 µM (IC50 
value) and 8 µM (2 × IC50 value) in the presence of 5 × 10
7 cells/ml of K. aerogenes. Tubes 
were incubated at room temperature (23 oC) for 72 hours. Samples were removed throughout 
the period, fixed with glutaraldehyde (0.5% v/v final conc.) and cells counted (see 2.2.1).  
Experiments were performed twice. The percentage cell survival in treated samples, 
compared to control, was determined for each time point, i.e. (number of treated cells at 
Tx/number of untreated cells at Tx) × 100, and plotted against time (h). 
 
2.4.2. Determining the susceptibility of T. pyriformis to PPAR agonists – MIC and IC50 
 
Triplicate samples of T. pyriformis (200 µL) were treated with a range of concentrations of 
OEA, PEA, GW0742 and Rosiglitazone. Numerous experiments were performed and each 
included triplicate untreated samples which acted as Controls. Tubes were incubated at room 
temperature (23 oC) for 90 minutes after which each tube was fixed and cells counted (see 
section 2.2.1). The percentage survival in treated samples, compared to control, was 
determined and from this, the IC50 and Minimum Inhibitory Concentration (MIC) values 






2.4.2.1. Determining the IC50 
 
Percentage inhibition (100% minus calculated % survival) was plotted against Log10 
agonist concentration in QtiPlot. The Logistic function tool was used to provide 
information on the significance of the data (p-value), the IC50 (concentration at which 
inhibition is half maximum) and the slope of the curve.  
 
2.4.2.2. Determining the MIC   
 
All data on the slope of the IC50 curve were plotted in EXCEL as % survival vs agonist 
concentration. Linear regression analysis was applied and high/low points removed until 
the highest R2 was achieved. The MIC (x) was then determined from the equation of the 
line (y = mx + c) when y = 100% survival.  
 
2.4.3. Determining the lethal dose of PPAR agonists to T. pyriformis 
 
Triplicate samples of T. pyriformis (200 µL) were treated with a range of concentrations of 
OEA, PEA, GW0742 and Rosiglitazone; above those concentrations which gave an apparent 
0% survival after 90 minutes (in 2.4.2). Numerous experiments were performed and each 
included triplicate untreated samples which acted as Controls. Tubes were incubated at room 
temperature (23 oC) for 72 hours after which the contents of each tube were examined with a 
light microscope (×40 magnification) for evidence of surviving cells. The lowest agonist 
concentration which resulted in 0% cell survival after 72 hours was considered to be the 
lethal dose.  
 
2.4.4.  Investigating potential molecular targets for agonists in T. pyriformis 
 
Experiments were set up in the same way as described in 2.4.2, i.e. 90 minutes survival tests. 
The ciliate (in triplicate) was treated with the agonist (at its IC50 value) with and without pre-
treatment with a blocker. Controls containing blocker alone were also included. The 
percentage survival, compared to the control, was determined at 90 minutes.  
 
All experiments employed three replicates and were normally repeated three times (n = 9). A 
one-way ANOVA compared all treatments and then a post-hoc Tukey test examined 
differences between % survival of the (i) agonist alone vs agonist and antagonist and, (ii) the 
antagonist alone vs agonist and antagonist.  
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2.4.4.1.  PPAR receptor blocking  
 
The action of three known PPAR agonists (OEA [PPARα], GW0742 [PPARβ/δ] and 
Rosiglitazone [PPARγ]) together with AEA and CBD (all at their IC50 value) were 
examined in the presence and absence of three PPAR receptor antagonists (at 2 × IC50 
value). Each blocker was added to the ciliate culture for 10 minutes prior to adding the 
agonists. Controls containing blocker alone were also included. All experiments were 
performed three times.  
 
2.4.4.2. Dopamine receptor blocking  
 
The action of OEA (IC50, 45 µM) was examined in the presence/absence of Haloperidol 
(added 10 minutes prior to adding the OEA). A concentration of 90 µM (2 × IC50), and 
even 60 µM, Haloperidol proved too toxic to the ciliates so this blocker was added at a 
concentration of 30 µM (see section 3.4).  Controls containing blocker alone were also 
included. This experiment was performed twice.  
 
2.4.4.3.  H89 and PTX 
 
The action of OEA, AEA and CBD (at their IC50 values) was examined in the 
presence/absence of (i) H89 (at 10 µM with a 30 minutes pre-incubation time) and (ii) 
PTX (at 100 ng/ml with a 5 hours pre-incubation time). Controls containing blocker alone 
were also included. This was a preliminary experiment and only performed once. 
 
2.4.4.4.  Dose-response  
 
Any agonist found to be blocked by an antagonist was tested further for evidence of a 
dose response, i.e. agonist at IC50 and blocker at 10 µM, 1 µM, 0.1 µM, 0.01 µM and 
0.001 µM. Controls of blocker alone and agonist alone were included. Experiments were 





3.1. General response of T. pyriformis to PPAR agonist, using CBD as example 
 
The survival of T. pyriformis in the presence of 0 µM (Control), 4 µM (IC50 value) and 8 µM 
(2 × IC50 value) CBD was monitored over a 72 hours period (at 23 
oC) (Figure 3.1). The 
Control population size grew somewhat, due to the presence of K. aerogenes prey, hence 
%survival >100%. An immediate decline in cell survival was evident in CBD-treated cultures 





Figure 3.1: Percentage survival of T. pyriformis with 0, 4 and 8 µM of CBD over 72 hours 













































Cell survival was dose dependent being ca. 60% (4 µM CBD) and 0% (8 µM CBD) at 90 
minutes (Figure 3.1a). Therefore, a standard time of 90 minutes was used to test the survival 
of T. pyriformis in the presence of different concentrations of all agonists in this study.   
 
A survival of 0% at 90 minutes (with 8 µM) suggested that this concentration was lethal to 
the ciliate population. However, as seen in Figure 3.1b, the population recovered albeit not to 
the extent of the Control (even with 5 × 107 K. aerogenes/ml present). This ciliate 
concentration was therefore below the detection limit for ciliate counts (278 cells/ml) at 90 
minutes, leading to an apparent 0% survival. True lethality was therefore evaluated at 72 
hours for all agonists in this study.  
 
3.2. T. pyriformis susceptibility to PPAR agonists 
 
To test whether T. pyriformis might possess PPAR receptors, its susceptibility to known 
PPAR agonists was first tested: OEA and PEA bind to PPARα, GW0742 to PPARβ/δ and 
Rosiglitazone to PPARγ. The ciliate was subjected to a range of agonist concentrations and % 
survival determined at 90 minutes (for IC50, MIC and slope) and 72 hours (for lethal 
concentration). 
 
T. pyriformis was susceptible to all four PPAR agonists and IC50 curves (Figure 3.2) showed 
a classic dose response. From these graphs the IC50 and slope were determined in QtiPlot 
(Table 3.1). Linear regression analysis of the Hill slope value (Appendix 2) was used to 
determine the MIC (Table 3.1) whilst survival over 72 hours was used to determine the lethal 
dose (Table 3.1).   
 
All data are summarized in Table 3.1. This also includes previously determined data for the 
action of AEA and CBD at 90 minutes on the same T. pyriformis strain (under the same 
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Figure 3.2: Percentage inhibition of T. pyriformis after 90 minutes exposure to varying 
agonist concentrations: a) OEA, b) PEA, c) Rosiglitazone and d) GW0742. 
 
The MICs and IC50 values suggest that the most potent agonist is AEA, followed by CBD, 
GW0742 and then OEA. Both PEA and Rosiglitazone, although eliciting a response in the 
ciliate, have parameter values much higher than those previously published for other cell 
types (see Section 4.3). For example, not even a concentration of 400 µM PEA proved lethal 
to the ciliate. PEA and Rosiglitazone were removed from the study at this point. OEA was 
retained, even though 205 µM was required to prove lethal to the ciliate.  
 
 
Table 3.1: The MIC, IC50, slope of the IC50 curve and lethal dose values for OEA, PEA, GW0742, 
Rosiglitazone (PPAR agonists) with T. pyriformis. Data for AEA and CBD included (obtained from 
Shruthi Sivakumar and Ashley Jones, Lancaster University). 
  
Agonists 
  AEA OEA PEA GW0742 Rosiglitazone CBD 
MIC (µM) 1.17 18.49 55.11 8.95 103.69 3.16 
IC50 (µM) 3.78 46.78 180.39 11.88 181.08 4.38 























3.3.   PPAR receptors as potential targets for agonists in T. pyriformis  
 
To further evaluate whether T. pyriformis might possess PPAR-like receptors, 90 minute 
survival experiments were performed in the presence of OEA, GW0742, AEA and CBD 
with/without a 10 minute pre-incubation of the ciliate with each of three specific PPAR-
receptor antagonists: GW 6471 (PPAR blocker), GSK 3787 (PPAR/ blocker), and 
T0070907 (PPAR blocker [T007]). Initial experiments used each blocker at a concentration 
twice that of the agonist’s IC50. Then, if a blocking of the negative effect of the agonist was 
recorded, the antagonist was tested at concentrations of 10, 1, 0.1, 0.01 and 0.001 µM.  
 
3.3.1. OEA  
 
OEA was tested at its IC50 of 45 µM and antagonists at 90 µM. In the presence of OEA 
(Figure 3.3, hatched bars), the survival of T. pyriformis in the absence of blockers was 37.82 
± 12.44%, which was significantly different to the untreated control (Figure 3.3, 0 µM, solid 
bar) (P = 0.001). Pre-incubation with each blocker alone had no significant negative effect, 
compared to the control (P = 0.22 - 0.90), and did not alleviate the negative effect of OEA. 
The % survival value with GSK3787 [β/δ] was not significantly different to OEA alone (P = 
0.90) but values were significantly lower than OEA alone with GW6471 [α] and T007 [γ] (P 
= 0.023 and 0.007, respectively). No dose-response experiment was carried out.  
 
Figure 3.3: Percentage cell survival of T. pyriformis in the presence of 45 µM OEA (hatched 
bars) with and without pre-incubation with 90 µM of each PPAR receptor blocker, GW6471 
(PPARα), GSK3787 (PPARβ/δ) and T007 (PPARγ). Solid bars denote % survival in the 
absence of OEA with/without each blocker. Error bars = SEM, n = 9. ^ Significantly different 


























GW0742 was tested at 15 µM and antagonists at 30 µM. In the presence of GW0742 (Figure 
3.4, hatched bars), the survival of T. pyriformis in the absence of blockers was 52 ± 11%, 
which was significantly different to the untreated control (Figure 3.4, 0 µM solid bar) (P = 
0.001). Pre-incubation with each blocker alone had no significant negative effect, compared 
to the control (P = 0.20 - 0.90), but totally alleviated the negative effect of GW0742 with % 
survival in their presence being equivalent to the control (P = 0.36 - 0.9) and significantly 
higher than GW0742 alone (P = 0.001 in all cases).   
 
Figure 3.4: Percentage cell survival of T. pyriformis in the presence of 15 µM GW0742 
(hatched bars) with and without pre-incubation with 30 µM of each PPAR receptor blocker, 
GW6471 (PPARα), GSK3787 (PPARβ/δ) and T007 (PPARγ). Solid bars denote % survival in 
the absence of GW0742 with/without each blocker. Error bars = SEM, n = 9. * Significantly 
different (P < 0.01) to GW0742 alone (no tests were significantly different to blocker alone).                                    
 
Each blocker was further tested at concentrations ranging from 10 to 0.001 µM (Figure 3.5).  
 
The PPARα blocker GW6471 completely alleviated the negative effect of GW0742 at 10 
µM, i.e. 100% survival, where GW0742 with blocker was not significantly different to 
blocker alone, only GW0742 alone (Figure 3.5a*).  No blocking effect was seen at 1 µM and 
lower, suggesting an MIC of >1<10 µM and that any dose-response might have been 
























          
Figure 3.5: Percentage survival of T. pyriformis in the presence of GW0742 (hatched bars), 
with and without pre-incubation with each PPAR receptor blocker (10 to 0.001 µM): a) 
GW6471 (PPARα), b) GSK3787 (PPARβ/δ) and c) T007 (PPARγ). Solid bars denote % 
survival in the absence of GW0742 with/without each blocker. Error bars = SEM, n = 9. 
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The PPARβ blocker GSK3787 and the PPARγ blocker T007 data completely alleviated the 
negative effect of GW0742 at 10 and 1 µM (Figure 3.5b-c*).  No blocking effect was seen at 
0.1 µM and lower, suggesting an MIC of >0.1<1 µM in both cases and that any dose-




AEA was tested at 4 µM and antagonists at 8 µM. In the presence of AEA (Figure 3.6, 
hatched bars), the survival of T. pyriformis in the absence of blockers was 61.06 ± 0.71%, 
which was significantly different to the untreated control (Figure 3.6, 0 µM solid bar) (P = 
7.4 × 10-8). Pre-incubation with each blocker significantly alleviated the negative effect of 
AEA; % survival values (with blocker) were significantly different to AEA alone (P = 0.001 
in all cases) and % survival (with AEA) were not significantly different to those in the 
presence of blocker alone (P = 0.09 - 0.31).  
 
Figure 3.6: Percentage cell survival of T. pyriformis in the presence of 4 µM AEA (hatched 
bars) with and without pre-incubation with 8 µM of each PPAR receptor blocker, GW6471 
(PPARα), GSK3787 (PPARβ/δ) and T007 (PPARγ). Solid bars denote % survival in the 
absence of AEA with/without each blocker. Error bars = SEM, n = 9. *Significantly different 
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Figure 3.7: Percentage survival of T. pyriformis in the presence of AEA (hatched bars), with 
and without pre-incubation with each PPAR receptor blocker (10 to 0.001 µM): a) GW6471 
(PPARα), b) GSK3787 (PPARβ/δ) and c) T007 (PPARγ). Solid bars denote % survival in the 
absence of AEA with/without each blocker. Error bars = SEM, n = 9. *Significantly different 

























































































The PPARβ blocker GSK3787 and the PPARγ blocker T007 data completely alleviated the 
negative effect of AEA at 10 and 1 µM (Figure 3.7b-c*).  No blocking effect was seen at 0.1 
µM and lower, suggesting an MIC of >0.1<1 µM in both cases and that any dose-response 
might have been expected within these concentrations.   
 
The PPARα blocker GW6471 completely alleviated the negative effect of AEA at 10, 1 and 
0.1 µM, i.e. 100% survival, where AEA with blocker was not significantly different to 
blocker alone (Figure 3.7a); suggesting an MIC >0.01<0.1 µM. However, only at 1 and 10 
µM was % survival with AEA and blocker significantly different to AEA alone (Figure 
3.7a*); suggesting an MIC of >0.1<1 µM. It is therefore difficult to conclude what the real 




CBD was tested at 4 µM and antagonists at 8 µM. In the presence of CBD (Figure 3.8a, 
hatched bars), the survival of T. pyriformis in the absence of blockers was 43.14 ± 8.39%, 
which was significantly different to the untreated control (Figure 3.8a, 0 µM solid bar) (P = 
0.0003). Only pre-incubation with GW6471 (PPARα receptor blocker) alleviated the negative 
effect of CBD and the % survival value (with GW6471) was significantly different to CBD 
alone (P = 0.001). A concentration of 8 µM GW6471 (with CBD) yielded a % survival value 
that was not significantly different to that in the presence of GW6471 alone (P = 0.90). 
 
In the dose response experiments (Figure 3.8b) the blocker completely alleviated the negative 
effect of CBD at 1 and 10 µM, i.e. 100% survival, where CBD with blocker was not 
significantly different to blocker alone, only CBD alone (Figure 3.8b*).  No blocking effect 
was seen at 0.1 µM and lower, suggesting an MIC of >0.1<1 µM and that any dose-response 





            
Figure 3.8: Percentage survival of T. pyriformis in the presence of CBD (hatched bars), with 
and without pre-incubation with a) GW6471 (α), GSK3787 (β/δ) and T007 (γ) at 8 µM and b) 
GW6471 (α) at 10 to 0.001 µM. Solid bars denote % survival in the absence of CBD 
with/without each blocker. Error bars = SEM, n = 9. * Significantly different (P < 0.01) to 




Table 3.2 summarizes the concentrations of antagonists required to elicit a positive 
alleviation of an agonist’s effect on T. pyriformis (MIC) and that required to completely 
alleviate its action (100% block). Evidence for the existence of all three PPAR receptor types 
in T. pyriformis was obtained with GW0742 and AEA responding to the blocking of all three. 
The action of GSK3787 (β/δ) against these agonists was remarkably similar to that of T007 





















































(α); AEA was more sensitive to the blocking (Table 3.2). The action of CBD was only 
blocked with GW6471 (α) at a comparable MIC to that of AEA. 
 
Table 3.2: A summary of the range of Minimum Inhibitory Concentrations (MIC, µM) of each PPAR 
antagonist with each agonist and the concentration (100% block, µM) of antagonist required to completely 
alleviate the negative action of the agonist on T. pyriformis.  
Agonist PPAR Antagonists (μM)     
  GW6471(α) GSK3787(β/δ) T0070907(γ) 
 MIC 100% block MIC 100% block MIC 100% block 
OEA - - - - - - 
CBD >0.1<1  >0.1<1 - - - - 
GW0742 >1<10  >1<10 >0.1<1 >0.1<1 >0.1<1 >0.1<1 
AEA >0.01<1  >0.1<1 >0.1<1 >0.1<1 >0.1<1 >0.1<1 
  
 
3.4. Dopamine receptor  
 
The action of OEA (45 µM) on T. pyriformis was examined in the presence/absence of 
Haloperidol (HPD) using standard 90 minutes survival experiments, as described in Section 
3.3, with the caveat that because this was a preliminary experiment it was performed twice 
(in triplicate, n = 6). A concentration of 90 µM HPD (2 × IC50) proved too toxic to the ciliate 
(Figure 3.9), but at 60 µM and below it was not. A concentration of 30 µM was chosen to 
accompany the standard dose response concentrations of 10 to 0.001 µM.  
 
Figure 3.9: Preliminary experiment of the effect of HPD on T. pyriformis. Percentage 
survival of T. pyriformis in the presence of HPD alone and at concentrations 0-90 µM. Error 


































The presence of HPD enhanced the negative effect of OEA (Figure 3.10). This was 
significant for concentrations of 30, 10, 1 and 0.1 µM HPD whilst concentrations of 0.01 and 
0.001 µM HPD had no effect. This relationship was not investigated further. 
 
   
Figure 3.10: Percentage survival of T. pyriformis in the presence of OEA (hatched bars), with and 
without pre-incubation with Haloperidol at 30 to 0.001 µM. Solid bars denote % survival in the 
absence of OEA with/without Haloperidol. Error bars = SEM, n = 3. * Significantly different (P < 
0.05) to OEA alone (all tests were significantly different to Haloperidol alone).  
 
 
3.5. G protein-coupled receptor  
 
The action of OEA (45 µM), AEA (4 µM) and CBD (4 µM) on T. pyriformis was examined 
in the presence/absence of H89 at 10 µM (with a 30 minutes pre-incubation time) and PTX at 
100 ng/ml (with a 5 hours pre-incubation time), using standard 90 minutes survival 
experiments (Section 3.3).  This was a preliminary experiment and was only performed once 
(in triplicate, n = 3).  
 
The presence of H89 did not significantly alleviate the negative effect of any agonist (Figure 
3.11) and % survival with agonist plus H89 was always significantly lower than with H89 
alone. PTX alleviated the negative effect of OEA only, yielding a significantly higher 
























alone (P = 0.014); so not completely alleviated. PTX had no significant effect on the action of 
CBD and AEA.  
Figure 3.11: Percentage survival of T. pyriformis in the presence of OEA (45 µM), CBD (4 
µM) and AEA (4 µM) with/without pre-incubation with PTX (100 ng/ml) and H89 (10 µM). 
‘Controls’ are no agonist or antagonist (blue), PTX alone (orange) and H89 alone (grey).  Error 




3.6. Summary of results 
 
Table 3.3: Summary of the effect of blockers on the survival of T. pyriformis in the presence of 
cannabinoids and PPAR agonists. 
Agonists PPAR Haloperidol PTX H89 
α β/δ γ 
OEA Negative No effect Negative Negative Positive No effect 
CBD Positive No effect No effect N/A No effect No effect 
AEA Positive Positive Positive N/A No effect No effect 




























4.1.  Summary of major findings 
 
The aim of this study was to investigate the effect of six cannabinoids/ligands on T. 
pyriformis and whether this involved peroxisome proliferator-activated receptors (PPARs), G 
protein-coupled receptor (GPCRs), and/or a dopamine receptor. Firstly, the lethal effect of 
the ligands was determined through four parameters 1) MIC, 2) IC50, 3) Hill slope value, and 
4) lethal concentration (Table 3.1). Results suggest that T. pyriformis was most susceptible to 
AEA, followed by CBD, then GW0742, then OEA. PEA and Rosiglitazone proved to be less 
lethal to T. pyriformis and were thus, eliminated from the study. As for the other 
cannabinoids, the slope values suggested that OEA and CBD behave similarly and might 
bind to the same target, whereas AEA and GW0742 might each bind a distinct target.  
 
The study then went on to determine the ligands’ target, whether PPAR, GPCR, and/or a 
dopamine receptor, using specific blockers to inhibit these receptors (Table 3.3). Haloperidol 
(Dopamine blocker) and H89 (PKA blocker) demonstrated no blocking of the effect of any 
agonist. In contrast, PPAR blockers alleviated the negative effects of AEA, CBD, and 
GW0742, but not OEA. Results suggested that AEA and GW0742 could interact with all 
three PPAR types (⍺, β/δ, and γ) whereas CBD only interacted with PPAR⍺. In the presence 
of Pertussis toxin (G⍺i/o blocker) only the effect of OEA was alleviated. This suggests that 
the ciliate might have at least two pathways for responding to these ligands; CBD, AEA and 
GW0742 might use a PPAR-like pathway, while OEA targets GPCRs.  
 
4.2. Lethal effect of cannabinoids on protists  
 
Taking CBD as an example, the ciliate population reduced to 60% (compared to the control) 
with 4 µM CBD, and to ‘0%’ with 8 µM CBD, in the first 90 minutes. After this the 4 µM-
treated population density remained stable while that of the 8 µM-treated population 
gradually increased, indicating that not all the cells in that population had been killed and that 
the population had been below the limit of detection at 90 minutes. The concentration of 
CBD found to be lethal to the whole population was 40 µM. 
 
Previous studies have also shown that cannabinoids are toxic to protists and that the negative 
effect can be short-term. The treatment of T. pyriformis with THC elicited a dose dependent 
response (between 3.2 – 24 µM) with the cells showing a change in shape, having sluggish 
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movement and a decreased level of cellular growth and division (McClean & Zimmerman, 
1976). However, even at the highest concentration (24 µM THC) this only caused an 11% 
reduction in cell concentration after 16 hours growth, suggesting that the IC50 is higher than 
24 µM (McClean & Zimmerman, 1976). Comparing this to the current study suggests that T. 
pyriformis is more susceptible to CBD (IC50, 4.38 µM) than THC. The toxic effect on T. 
pyriformis was also transient in both studies. In the current study, cells appeared to be in 
recovery by 10 hours, whereas in the study of McClean & Zimmerman (1976) cells recovered 
after ‘several hours’, although the actual time period was not stated.  
 
THC has also been reported to inhibit the growth in several amoebae. At 60 µM THC cells of 
the slime mould Dictyostelium discoideum, which has an amoeboid form in its growth cycle, 
became round and immobile but after a ‘few hours’ (time not stated) they fully recovered 
(Bram and Brachet, 1976). However, at 50 µM of Cannabinol, cells rounded up but they did 
not recover, suggesting different effects depending on the cannabinoid used (Bram and 
Brachet, 1976). Even so, D. discoideum appears less sensitive to cannabinoids than T. 
pyriformis.  
 
With the amoeba-flagellate Naegleria fowleri, the presence of phytocannabinoids prevented 
enflagellation and encystment but movement remained the same (Pringle et al., 1979). Three 
days exposure in the presence of 5 µg/mL (16 µM) THC and CBD resulted in populations 
which were 54% and 27% that of the control, respectively, suggesting that the IC50 of THC 
was ca. 16 µM while that of CBD was <16 µM (Pringle et al., 1979). This once again 
suggests that CBD is more toxic than THC and that T. pyriformis is more sensitive to CBD 
than these amoebae.  
 
The endocannabinoid AEA has also been shown to inhibit growth of three other species of 
amoebae: Vermamoeba (Hartmannella) vermiformis, Acanthamoeba castellanii, and 
Willaertia magna with IC50 values (determined after 3 days exposure) of 14 µM, 17 µM, and 
20 µM, respectively (Dey et al., 2010). In the current study, the IC50 of AEA was only 4 µM, 








4.3.    Lethal effect of cannabinoids on cancer cells 
 
Cannabinoids are considered to act more specifically to cancer cells than normal cells and 
much work has examined their effect on human cancerous cells (Ryberg et al. 2007; 
Chakravarti et al., 2014; Almada et al., 2017; Scott et al., 2017). The lung carcinoma cell line 
(A549) can be killed by THC at concentrations of 32 µM (IC50 of 24 µM) (Sarafian et al., 
2002). Human leukemia cancer cell lines CEM and HL60 are more sensitive. When these 
cells were treated with THC, CBD and cannabigerol (CBG) the IC50 values for CEM cells 
were 13 µM, 8 µM, 11 µM for THC, CBD, and CBG, respectively while values for HL60 
were slightly higher at 15 µM, 12 µM, 16 µM, respectively (Scott et al., 2017). In both cell 
types, CBD shown to be more toxic than THC; a similar response to that observed in 
amoebae (Pringle et al., 1979).  
 
In human glioma cells, 10 µM CBD was the non-inhibitory value for growth while 25 µM 
CBD was ‘inhibitory’ suggesting an MIC >10<25 µM (Massi et al., 2006). Induction of 
apoptosis was via upregulation of caspase-3 activity which ultimately causes apoptotic 
mediated cell death (Massi et al., 2006). Human prostate carcinoma cells (PC-3, DU-145, 
22RVI and LNCAP) appear to be more sensitive, being induced into apoptosis at CBD 
concentrations of 1 - 10 µM (De Petrocellis et al., 2000). The same study found that lower 
concentrations (0.5 - 6 µM) of AEA resulted in cell death; a similar response was observed 
with T. pyriformis exposed to AEA and CBD (MICs of 1.17 and 3.16 µM, respectively). 
Interestingly, cell death with AEA was not due to apoptosis but was instead due to AEA 
inhibiting the G1/S phase of cell division (De Petrocellis et al., 2000). Although comparable 
studies with AEA have not been performed with protists, it is interesting to note that the cells 
of T. pyriformis were most susceptible to THC during their G2 phase of cell division 
(Zimmerman et al., 1981). 
 
The observed inhibitory effects of cannabinoids on cancer cells mirror those observed with 
protists. For example, the following trends are shared by both: (i) CBD is more toxic than 
THC, (ii) AEA is more toxic than CBD, (iii) different cell types show differences in 
susceptibility and, (iv) cell death occurs with cannabinoid concentrations in the lower end of 
the µM range. Since phylogenetic studies suggest that protists do not possess the main 
endocannabinoid receptors (McPartland et al., 2006), and cannabinoids can act upon 
mammalian cells without the need for receptors (Sanchez et al. 1998; De Pretrocellis et al., 
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2000), it is intriguing to discover what their target is in protists and how this results in cell 
death. 
 
4.4     Mechanisms of cell death in Tetrahymena 
 
In the ciliate T. thermophila, programmed nuclear death (PND) mainly occurs during 
conjugation (sexual reproduction) and involves an apoptosis inducing factor (AIF), and 
endonuclease G (EndoG) in the mitochondria, resulting in macronucleus degeneration 
(Akematsu et al., 2012). Although T. pyriformis is not capable of sexual conjugation 
(Nanney, 1974) it might still possess the same PND mechanism as that exhibited by T. 
thermophila, which is similar to programmed cell death (PCD) in multicellular organisms. In 
mammalian cells, the macronucleus is degraded via chromatin condensation and DNA 
fragmentation with the help of AIF, EndoG and caspases (Akematsu et al., 2012). However, 
T. thermophila does not possess caspases (Eisen et al., 2006) and PND is considered to occur 
via a caspase-independent route involving either AIF or EndoG (Akematsu et al., 2012).  
 
In a caspase independent pathway, many mitochondria move towards the parental 
macronucleus and AIF is released from their inter membrane space which is then translocated 
into the nucleus and results in nuclear condensation and large-scale DNA fragmentation 
(Akematsu et al., 2012). Electron microscopic studies have also revealed the presence of 
autophagosomes surrounding this degenerating macronucleus during Tetrahymena 
conjugation (Weiske-Benner and Eckert, 1987) suggesting that autophagy might play a direct 
role in PND in Tetrahymena.  
 
Autophagy is a major degradative pathway which recycles cytoplasmic compartments by 
using the double membrane structure (the autophagosome) to fuse with the vacuole/lysosome 
(Yorimitsu and Klionsky 2005). Caco-2 cells have been shown to activate autophagosome 
arrangement between 4-6 hours after treatment with 10 µM CBD while 25 µM CBD led to 
over-expression of LC3-II protein which resulted in cell death (Koay et al., 2014). In protists, 
the degradative pathway can be upregulated by stress, with the main one being nutrient 
limitation. Under such conditions increased levels of autophagosomes have been recorded in 
both Tetrahymena (Nilsson, 1984; Zhang et al., 2015) and D. discoideum (King et al. 2011, 
Mesquita et al., 2013). This pro-survival characteristic of autophagy maintains tissue 
homeostasis and sustains cell viability under stressful conditions but when failing to restore 
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homeostasis, autophagy leads to cell death through the autophagic cell death (ACD) pathway 
(Levine & Kroemer, 2008). In T. thermophila, such autophagic cell death has been recorded 
in the presence of H2O2, Oligomycin and vitamin K3 but the molecular basis that regulates 
this, especially the genes responsible, have not been identified (Zhang et al., 2015).  
However, this study did correlate enhanced autophagic cell death to an accumulation of 
reactive oxygen species (ROS) resulting from possibly a blockage of mitochondrial electron 
transport (Zhang et al., 2015).   
 
Components of the mitochondrial respiratory chain have been identified as molecular targets 
of cannabinoids (Bih et al., 2015). THC is a known inhibitor of NADH oxidase activity in 
mitochondria and above a threshold concentration (0.4 µM THC), can deplete energy (ATP) 
levels in cells which can lead to cellular death (Bartova & Birmingham, 1979).  Human lung 
cancer cells (H460) treated with THC, and indeed AEA, show a concentration dependent 
decrease in the mitochondrial oxygen consumption with maximum effect at 20 µM 
(Athanasiou et al., 2007). Studies have also shown that CBD modulates several cytochrome 
P450 enzymes (Usami et al., 2008).  
 
Finally, THC, AEA and 2-AG can exert their effects on human cells through inhibition of 
adenyl cyclase activity (Koh et al., 1997; Pisanti et al., 2013). Tetrahymena have been shown 
to contain a novel adenyl cyclase ion channel fusion protein, localized to ciliary membranes 
through which cAMP formation is stimulated by an ion conductance (Weber et al., 2009). 
Therefore, inhibition of this adenylase cyclase activity at this site might explain the lowered 
cAMP levels in THC treated T. pyriformis (Zimmerman et al., 1981), the sluggish movement 
of T. pyriformis cells in the presence of THC (McClean & Zimmerman, 1976) and CBD 
(Parry, personal communication), and the loss of T. thermophila’s avoidance response to 
chemorepellents (Keedy et al. 2003).  
 
There are therefore many mechanisms by which Tetrahymena cells can die and also many 
ways in which cannabinoids can induce such death. The current study primarily examined the 
possible involvement of PPARs on ciliate cell death, as their interaction with cannabinoids 





4.5.  Involvement of receptors in cell death 
  
The Hill slope (IC50 slope factor) indicates the cooperativity/cooperative binding of the 
ligand. Cooperative binding occurs when binding of the first molecule (either identical or 
nearly identical) to a receptor changes the binding affinity for the second molecule, either 
positive or negative (Stefan and Le Nove`re, 2013). For example, the binding of one oxygen 
to the first hemoglobin’s binding site increases the binding affinity (or also known as increase 
cooperativity) of oxygen to the three remaining binding sites (Stefan and Le Nove`re, 2013). 
In general, a Hill slope value of greater than 1 indicates positive cooperativity, whereas a 
value lesser than 1 indicates a negative cooperativity.  
 
In this study, all agonists yielded positive slope values and so, all agonists induced a 
cooperative binding effect. OEA and CBD had similar slope values (7.86 and 8.11, 
respectively), suggesting they bind at a similar pace to the receptor, and might possess the 
same target(s) (Table 3.1). Although this might suggest that T. pyriformis possesses a 
PPARα-like receptor, PEA (which also binds to PPARα) did not behave similarly to OEA 
and its slope (5.28) was closer to that of Rosiglitazone (5.69) suggesting PEA and 
Rosiglitazone might share the same target(s) (Table 3.1). Thus, this suggests that there could 
be multiple targets for the endocannabinoid pathways in T. pyriformis.  
 
4.5.1 PPARs  
 
PPARs are mainly involved in the metabolism of fatty acids and carbohydrates, however, 
there is evidence that activation of PPARs is also involved in cell line proliferation and 
apoptosis (Stephen et al., 2004; Brunetti et al., 2019). Studies have shown that activation of 
PPARs can result in cytotoxic effects on various cancerous cell lines (Kim et al., 2007), and 
anticancer agents are being developed from this concept.  
 
In the current study, all three PPARs were suggested to be involved in the mechanism by 
which AEA, CBD and GW0742, but not OEA caused cell death in the ciliate population. In 
the presence of GW6471 (PPARα blocker), the negative effects of CBD, AEA and GW0742 
were alleviated. However, GSK3787 (PPARβ/δ blocker) and T0070907 (PPARγ blocker) 
were only able to block the effect of AEA and GW0742. These results bore no resemblance 
to the predictions made based on the IC50 slope values. 
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These results also contradict those obtained from similar studies in mammalian cells (Pertwee 
et al., 2010; O’Sullivan, 2016). In these systems, OEA is reported to induce activation of all 
PPAR isoforms (O’Sullivan, 2016) but this was not recorded in the current study. AEA is 
also considered an agonist of PPARα and PPARγ, but not PPARβ/δ, with the potency (IC50) 
of 10 – 30 µM and 8 – 10 µM, respectively (Pertwee et al., 2010). In T. pyriformis, the action 
of AEA was 100% blocked at a much lower concentration (≤1 µM) and with all three 
blockers. The highly selective PPARβ/δ agonist (GW0742) is reported to interact with human 
PPARβ/δ, - α, and -γ, with EC50 values of 0.001, 1.1, and 2 µM, respectively (Sznaidman et 
al., 2003). The current study also found an interaction with the three PPAR types, with the 
effect of GW0742 being 100% blocked by all three antagonists, but the concentrations 
required were variable. GW0742 did not appear to be ‘highly selective’ for PPARβ/δ as the 
concentration required for 100% blocking was equivalent to that for PPARγ (≤1 µM), 
whereas ≤10 µM was required to block PPARα. Finally, CBD is reported to only activate 
PPARγ in the mammalian system (O’Sullivan et al., 2009a), with an IC50 of 5 µM 
(O’Sullivan et al., 2009b), yet in the current study its activity was 100% blocked by only the 
PPARα antagonist and at a lower concentration (≤1 µM).  
 
Nonetheless, the results of the PPAR blocking study indicated that there was an alleviation of 
cell death in T. pyriformis by the PPAR antagonists and thus suggests that T. pyriformis either 
possesses, 1) all three PPAR isoforms, or 2) possibly one isoform which can bind all three 
agonist/antagonist types. To date, the three PPAR isoforms have only been reported in bony 
fish, mammals, birds, and amphibians (Zhou et al. 2015); not in invertebrates. This suggests 
that T. pyriformis might not possess all three, but a PPAR isoform that can bind all three 
agonists/antagonist types. PPARs are known to have a ligand-binding domain which is 
relatively spacious and promiscuous, binding a number of ligands at different sites (Itoh et 
al., 2008). It might be that even though all three agonists/antagonists can bind to this PPAR 
they bind at different sites. For example, CBD might bind at the site that is the same as 
GW6471 (the PPARα blocker) but the other two blockers do not bind to this particular site 
and therefore do not interfere with the binding of CBD. 
 
However the ligand binds, it can exert an effect through both PPAR‐dependent (genomic) 
and PPAR‐independent (non‐genomic) mechanisms. The classical genomic mechanism 
involves PPAR interacting with the retinoid X-receptor (RXR) to form a heterodimer 
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followed by the activation of target gene transcription (Grygiel-Górniak, 2014). The non-
genomic, and more rapid, mechanism involves ligand activation of PPARs that leads to the 
suppression of other gene expression by antagonizing transcription factors (Campand and 
Tafuri, 1997).  
 
With regards to the latter, activation of PPARα and γ has been shown to directly antagonize 
the NF‐κβ pathway in many types of cancer cells (Camp et al., 1999; Lau et al., 2002; 
Chandran et al. 2016; Morinishi et al. 2019). NF-κB belongs to a highly conserved family of 
transcription factors which, when activated, rapidly translocate into the nucleus and induces 
the transcription of various cellular genes (Pahl, 1999). Ligand binding to PPARα and γ has 
also been shown to inhibit of the activation, and nuclear translocation, of mitogen-activated 
protein (MAP) kinases, leading to apoptosis in cancer cells (Chinetti et al., 1998; Su et al., 
1999), with the main MAPKs being p42/p44 (ERK1/2) (Takedaet al., 2001; Chandran et al. 
2016). ERK1 and ERK2 have been shown to be key mediators of signal transduction, 
transmitting signals from the cell surface to the nucleus in human cells (Lenormand et al. 
1998; Volmat et al. 2001).  
 
Considering protists are not known to possess RXR nor NF-κB, but T. thermophila possesses 
numerous MAPKs including putative ERK1/2 subfamily MAPKs (www.ciliate.org), it makes 
the latter a possible pathway by which cell death occurs in this protist.  
 
In addition to affecting the NF-κB and MAPK pathways, and inducing apoptosis, ligand 
binding to both PPARα and γ has been shown to induce G0/G1 cell cycle arrest leading to the 
death of cancer cells by reducing the levels of various cell-cycle regulating cyclins, 
specifically cyclinD1, A and E (Aboud et al. 2013; Chandran et al. 2016). Although arrest at 
the G0/G1 phase is the most commonly reported, cell cycle arrest can occur at the G1/S phase 
(De Petrocellis et al., 2000; Wakino et al. 2000).  
 
The role of PPARβ/δ in cell death is controversial. Some studies have suggested that 
PPARβ/δ agonists and antagonists demonstrate anticancer effects (Zaveri et al., 2009), while 
others report that PPARβ/δ stimulate proliferation and suppress pro-apoptotic events in the 
development of colon, breast and prostate cancer (Stephen et al., 2004; Sertznig et al., 2007). 
Ligand activation of PPARβ/δ with GW0742 has also been shown to prevent cell cycle 
progression from G1 to S phase in keratinocyte cells (Burdick et al., 2007).   
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PPARs are also involved in fatty acid oxidation and adipogenesis, which makes them 
important molecular targets in the treatment of obesity and diabetes (Grygiel-Górniak, 2014).  
 
OEA is reported to induce activation of all PPAR isoforms in mammalian cells, with the 
highest affinity for PPARα (O’Sullivan, 2016) but this was not recorded in the current study. 
Further research examined whether GCPRs and the Dopamine receptor might be involved in 
the action of OEA on Tetrahymena cells.  
 
4.5.2 G protein-coupled receptor 
 
GPCRs are members of the superfamily of 7-transmembrane receptors (7-TMR) (Morales et 
al., 2018) and can be blocked with the Pertussis toxin (PTX). PTX is derived from bacterium 
Bordetella pertussis and it acts by modifying the natural function of GCPRs, specifically 
catalyzing the ADP-ribosylation of a cysteine residue on the α-subunit of Gi/o (Reisine and 
Law, 1992). The subunit Gαi is not affected by PTX (Reisine and Law, 1992).  
 
GPCRs are involved in many regulatory functions in humans such as growth, source of smell, 
taste, visual, behavioural, immune system and mood (Rosenbaum et al., 2009). Over 800 
GPCRs have been identified as being specific to a particular function (Fredriksson et al., 
2003). The ligands they bind range from light sensitive compounds, odours, pheromones, 
hormones, cannabinoids and even neurotransmitters (Rosenbaum et al., 2009), but even now 
some GPCR have unknown functions or unknown primary ligands, and are termed ‘orphan’ 
GPCRs. Since (i) GPCRs are involved in a wide array of regulatory functions, (ii) they can be 
activated by numerous ligands including cannabinoids, (iii) the main cannabinoid receptors 
CB1 and CB2 are both GCPRs (but are absent in Tetrahymena) and, (iv) homologues to GPR6 
and GPR37 have recently been identified T. thermophila (Lampert et al., 2011; Zou and 
Hennessey, 2017), it seemed sensible to carry out a preliminary investigation to evaluate 
whether GCPRs might be the target for OEA in Tetrahymena.   
 
Of the two GCPRs in Tetrahymena, GPR6 is considered a potential endocannabinoid as it 
shares a high amino acids sequence identity (35%) with CB1 and CB2 (Lee et al., 2001). CBD 
is considered to be an inverse agonist for GPR6 (Laun and Song, 2017) however, PTX had no 
effect on the interaction between CBD and T. pyriformis in the current study. Blocking with 
PTX also had no effect on the action of AEA, but this agrees with results for human cells 
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whereby AEA has not been shown to interact with GPR3, GPR6 and GPR12 (Brown et al., 
2017). Conversely, PTX alleviated the negative action of OEA on T. pyriformis suggesting it 
employs a pathway involving GCPRs whereas CBD and AEA employ a pathway involving 
PPARs.  
 
OEA can elicit a response in human cells via GPR119 which is phylogenetically related to 
cannabinoid receptors, and is only activated by fatty acid amides, including AEA, OEA and 
PEA, with OEA being the most efficacious (Overton et al., 2006). OEA binding to GPR119 
leads to activation of adenylyl cyclase, increased production of cAMP, and enhanced Protein 
Kinase A (PKA) activity (Usdin et al., 1993). However, in the current study the blocking of 
PKA with H89 had no effect on OEA-induced death of the ciliate. This has also been 
observed in breast cancer cells, i.e., activation of GPR119 has been shown to reduce the 
growth of these cells and induced apoptosis by suppressing autophagosome formation but, 
this is not blocked with cAMP/PKA inhibitors (Im et al., 2018). The authors suggested that 
apoptosis induction and autophagy inhibition by a GPR119 agonist might be related to 
changes in cancer cell metabolism instead of canonical signaling pathway(s) of GRP119 
because there was increased levels of lactate in the cells, due to glycolysis stimulation, which 
suppressed mitochondrial functioning (Im et al., 2018). Indeed, the fact that modulation of 
GPR119 is involved in glucose homeostasis in many cell types has led to the idea that 
GPR119 modulation might provide the basis for an anti-obesity and type 2 diabetes therapy 
(Overton et al., 2006).  
 
Being a preliminary study, it is difficult to speculate further regarding the OEA pathway in 
Tetrahymena and further study is warranted. 
 
4.5.3 Dopamine receptor 
 
This study investigated this possibility of OEA using a pathway involving the dopamine 
receptor, using the well-established Dopamine blocker, Haloperidol (HPD). The result was 
unlike that seen with PPAR/GPCR blockers in that the presence of HDP alone proved toxic 
to the ciliate at concentrations above 60 µM. A toxic effect has also been reported in 
RAW264.7 macrophage cells, but at a lower concentration (40 µM HPD), whereby a cellular 
increase in nitric oxide and caspases 8 and 3 resulted in the modulation of apoptosis (da Cruz 
Jung et al., 2015). HPD has also been shown to promote ferroptosis in hepatocellular 
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carcinoma cells at concentrations as low as 10 µM (Bai et al., 2017). Ferroptosis is a form of 
cell death, characterised by the accumulation of reactive oxygen species (ROS), cell volume 
shrinking and increased mitochondrial membranes during oxidative stress metabolism. 
During ferroptosis, the iron-dependent accumulation of ROS induces the activation of 
ferroptosis through glutathione peroxidase 4 (GPX4) or glutathione (GSH) deficiency (Bai et 
al., 2017). Haloperidol promotes ferroptosis through binding to the Sigma 1 receptor (S1R), a 
protein modulator associated with a wide array of neurological diseases and increases iron 
accumulation and lipid peroxidation (Collina et al., 2013). S1R has not been reported in 
Tetrahymena to date and this ciliate appears to be less sensitive to HPD than mammalian 
cells. 
 
When HPD was combined with OEA (45 µM) there was a significant reduction in the ciliate 
population, compared to OEA alone; reducing it to ~21% (with 0.001 and 0.01 µM HPD), 
~17% (with 0.1 and 1 µM HPD), and to ~15% and 1% in the presence of 10 µM and 30 µM 
HPD. This shows that HPD somehow enhanced the effect of OEA. This might suggest that 
there are multiple pathways involved, with possibly the activation of multiple binding targets 
by HPD. 
  
Although Haloperidol has a high affinity for the D2 receptor in mammalian cells (Ki = 1.2 
nM), it can target other Dopamine subtypes including D3, D4, D1 and D5 with Ki of ~7, 2.3, 
~80, and ~100 nM, respectively (Seeman and Van Tol, 1994; Ilyin et al., 1996). At the same 
time, HPD can also act on the Serotonin receptor and subtype-selective N-methyl-D-aspartate 
(NMDA) antagonist (Lynch and Gallagher, 1996). Only D1 and NMDA (involved in 
chemotaxis and Ca2+ signaling) has been shown to be present in Tetrahymena to date (Nam et 
al., 2009; Ud-Daula et al., 2012). Since HPD was not specific to a particular dopamine 
receptor (or D2 alone), and HPD-induced death might result in multiple death pathways 
future work is required needed to be conducted, with the use of more specific and separate 
blockers for dopamine and serotonin. 
 
4.6    Conclusions 
 
This study aimed to quantify and compare the lethal effect of selected PPAR agonists; OEA, 
PEA, AEA, CBD and two synthetic cannabinoids (GW0742 and Rosiglitazone) on 
Tetrahymena pyriformis. Results showed that the ciliate was most sensitive to AEA, followed 
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by CBD, GW0742 and OEA, with PEA and Rosiglitazone having little lethal effect. The 
MICs and IC50 values with T. pyriformis were of the same order as those concentrations 
required to elicit an effect in cancer cells. The effect on T. pyriformis was cell death, 
however, this was only observed for a 90 minutes period after which no net negative effect 
was recorded. 
 
The study then aimed to determine whether the negative response was elicited through a 
pathway involving PPARs, GCPRs and/or a dopamine receptor. Results showed that the 
action of AEA, CBD and GW0742 utilized a PPAR pathway whilst OEA possibly utilizes a 
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       NaCl                                 10 g 
       Agar No.2                         10 g 
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